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Sunday, September 18
4:00 - 6:30 p.m. Registration, Congressional Ballroom
6:00 - 8:00 p.m. Opening Reception, Congressional Ballroom

Monday, September 19
6:30 - 8:00 a.m. Continental breakfast, Congressional Ballroom
7:00 a.m. - 5:00 p.m. Registration, Congressional Ballroom
8:00 - 8:15 a.m. Kenneth White, PhD, Utah State University, USA
Summit Welcome and Opening Remarks
8:15 - 9:00 a.m. Michael Roberts, PhD, University of Missouri, USA
Keynote Lecture - The Current Status of Transgenic Farm Animal Research

Session 1: Gene Editing Technology and Application
Session Chair – Bruce Whitelaw, PhD, Roslin Institute, United Kingdom
9:00 - 9:30 a.m. Dan Carlson, PhD, Recombinetics Inc, USA
Efficient Genome Editing in Livestock
9:30 - 10:00 a.m. Göetz Laible PhD, AgResearch, New Zealand
Technological Advances Create New Opportunities for the Targeted Improvement
of Livestock
10:00 - 10:30 a.m. Bhanu Telugu, PhD, University of Maryland, USA
Engineering Genomes of Domestic Pigs for Agricultural Applications
10:30 - 10:45 a.m. Poster exhibit/beverage break, Senate Suites

Session 2: Modification of Disease Resistance and Susceptibility in Large
Animals
Session Chair – Chris Davies, DVM, PhD, Utah State University, USA
10:45 - 11:15 a.m. Kevin Wells, PhD, University of Missouri, USA
Improved Resistance to Livestock Disease through Genetic Enhancement
11:15 - 11:45 a.m. Jorge Piedrahita, PhD, North Carolina State University, USA
Development and Characterization of Severe Combine Immune Deficient Swine
11:45 a.m. - 12:15 p.m. Eddie Sullivan, PhD, SAb Biotherapeutics, USA
The Use of Genetically Engineered Large Animals to Rapidly Respond to Emerging
Infectious Disease through the Production of Therapeutic Antibodies
12:15 - 1:15 p.m.

Networking lunch – Congressional Ballroom
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Session 3: Transgenic Large Animal Models
Session Chair - Carol Keefer, PhD, University of Maryland, USA
1:15 - 1:45 p.m. Irina Polejaeva, PhD, Utah State University and Ravi Ranjan, MD, PhD,
University of Utah, USA
Transgenic Goat Model of Atrial Fibrillation
1:45 - 2:15 p.m. Randy Prather, PhD, University of Missouri. USA
Development of Animals Models and National Swine Research and Resource Center
Selected abstract presentations
2:15 - 2:30 p.m. Amy Desaulniers, University of Nebraska, USA
Use of Genetically Engineered Swine to Elucidate Testicular Function in the Boar
2:30-2:45 p.m. Seon-Ung Hwang, Chungbuk National University, Republic of Korea
Production of Transgenic Pigs with pGFAP-CreERT2; EGFPLoxP Inducible System
2:45 - 3:45 p.m. Poster session/refreshment break, Senate Suites

Session 4: Regulation of Genetically Engineered Large Animal Models and Medical
Device Development Tools
Moderator - Mark Walton, PhD, Yorktown Technologies, LP, USA
Presentations followed by a panel discussion.
3:45 - 4:15 p.m. Malini Wileman
4:15 - 4:45 p.m. Donna Lochner
4:45 - 5:15 p.m. Panelists include:
Malini Wileman, PhD, Center for Veterinary Medicine, FDA, USA
Donna Lochner, Center for Devices and Radiological Health, FDA, USA
Laura Epstein, J.D., Center for Veterinary Medicine, FDA, USA
Jill Ascher, DVM, MPH, Division of Veterinary Services, Center for Biologics Evaluation
and Research, FDA, USA.

Tuesday, September 20
6:30 – 8:00 a.m. Continental breakfast, Congressional Ballroom
7:00 - 10:00 a.m. Registration, Congressional Ballroom

Session 5: Current and Future Large Animal Models in Biomedical Research
Session Chair - Zhongde Wang, PhD, Utah State University, USA
8:00 - 8:30 a.m. David Ayares, PhD, Revivicor Inc., USA
Genetically Engineered Pigs for Xenotransplantation
8:30 - 9:00 a.m. Michael Cutler, DO, PhD, Intermountain Heart Institute, USA
Translational Cardiovascular Research Utilizing Large Animal Genetic Engineering

4

9:00 - 9:30 a.m. Chris Rogers, PhD, Exemplar Genetics, USA
TP53 and KRAS Targeted Pigs: A Platform for Models of Human Cancer
Selected abstract presentations
9:30 - 9:45 a.m. Timothy Sheets, University of Maryland, USA
Investigating the Conserved Role of Neurogenin 3 (NGN3) in Endocrine Pancreatic
Development in the Porcine Model Using CRISPR/Cas9 System
9:45 - 10:00 a.m. Min Yang, Utah State University, USA
Introduction of Callipyge Mutation into the Goat Genome Using Transcription
Activator-like Effector Nucleases (TALENs).
10:00 - 10:30 a.m. Poster session/beverage break, Senate Suites

Session 6: Funding Mechanisms to Support Genetically Engineered Livestock
Research
Moderator - Kenneth White, PhD, Utah State University, USA
Presentations followed by a panel discussion
10:30 – 10:50 a.m. Ravi Ravindranath
10:50 – 11:10 a.m. Adele Turzillo
11:10 – 11:30 a.m. Miguel Contreras
11:30 a.m. – 12:00 p.m. Panelists include:
Ravi Ravindranath, DVM, PhD, National Institutes of Health, Reproductive Sciences
Branch, USA
Adele Turzillo, USDA, National Institute of Food and Agriculture, USA
Miguel Contreras, PhD, National Institutes of Health, Office of Research Infrastructure
Programs, USA
Michael Roberts, PhD, Curator’s Professor of Biochemistry and Animal Sciences,
University of Missouri, Member of the National Academy of Sciences, USA
12:00 - 1:00 p.m.

Networking lunch, Congressional Ballroom

Session 7: Current and Future Large Animal Models in Biomedical Research
Session Chair - Jon Oatley, PhD, Washington State University, USA
1:00 - 1:30 p.m. Eckhard Wolf, University of Munich Gene Center, Germany
Genetically Tailored Pig Models for Translational Diabetes Research
1:30 - 2:00 p.m. Ann Harris, PhD, Feinberg School of Medicine, Northwestern University,
USA
Why Might New Large Animal Models of Cystic Fibrosis Be Useful for Generating
New Therapies?
2:00 - 2:30 p.m. Noelle Cockett, PhD, Executive Vice President and Provost, Utah State
University, USA
Future Perspectives and Closing Remarks
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Summit Welcome and Opening Remarks
Dr. Kenneth White, PhD, Utah State University, USA
Ken White is dean of the College of Agriculture and Applied Sciences at Utah State
University, the vice president for USU Extension and director of the Utah Agriculture
Experiment Station. Dr. White will open the summit and introducing the keynote speaker.
Dr. White is known for his partnership in creating the first successful equine clones. He is
also interested in research of early development and reproduction.

Keynote Lecture
Michael Roberts, PhD, University of Missouri
S1: The Current Status of Transgenic Farm Animal Research
R. Michael Roberts1, 2
1
Division of Animal Sciences and, University of Missouri, Columbia, MO, USA; 2Bond
Life Sciences Center, University of Missouri, Columbia, MO, USA
I will provide a brief and general account of transgenic research in farm animals, beginning
with approaches that introduced genetic material directly into a pronucleus of the fertilized
egg and concluding with gene editing by CRISPR/Cas9 technologies. Following this
introduction, I’ll cover the fraught topic of pluripotent stem cells, including the perceived
promise of such cells for transgenic research and the disappointing outcomes that have
followed the initial enthusiasm. I’ll conclude this section with an account of why I believe
such cells have continued relevance for both biomedical and agricultural purposes and
present recent data from mine and Dr. Randall Prather’s laboratory on an improved means
for in vitro maturation (IVM) of porcine oocytes. It is generally recognized that the
attainment of development competency in in vitro-derived oocytes continues to be a
challenge for assisted reproductive technologies (ART) in agriculturally important, large
farm species, because IVM oocytes are less competent than their in vivo counterparts,
particularly if they are derived from immature animals. I shall describe how three growth
factors (FGF2, LIF, IGF-1), when added to an otherwise standardized IVM medium, are
able to double the number of high-quality blastocysts that can be generated from a set
number of oocytes derived from immature gilts. These oocytes provide close to normal size
litters of healthy piglets following either somatic cell nuclear transfer or CRISPR/Cas9 gene
editing in the zygote. These cytokines work synergistically in promoting oocyte IVM and
induce hitherto unnoticed fluctuations of MAPK concentrations in cumulus cells (CCs)
investing the oocytes, a phenomenon that appears to underpin the observed improvement in
oocyte competence.
Michael Roberts is a Curators’ Professor of biochemistry and animal sciences at the
University of Missouri. He is a member of the National Academy of Sciences and
internationally recognized for the discoveries of interferon-tau and other pregnancyassociated proteins. He has published over 300 papers in refereed scientific journals and
over 70 reviews and book chapters. Dr. Roberts also received the prestigious Milstein Prize
for Research on interferons and the Wolf Prize in Agriculture.
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Session 1 - Gene Editing Technology in Livestock and Applications
Session Chair - Bruce Whitelaw, PhD, Roslin Institute, United Kingdom
Bruce Whitelaw was awarded a Bachelor of Science degree in Medical Microbiology from
the University of Edinburgh in 1982 and his PhD in 1987 from the University of Glasgow.
Currently, Bruce is head of Division of Developmental Biology at The Roslin Institute and
professor of Animal Biotechnology at the Royal (Dick) School of Veterinary Studies.
Having pioneered the use of lentivirus vectors for transgene delivery, he is currently
establishing robust methodology for genome editing in livestock.

Dan Carlson, PhD, Recombinetics Inc.
S2: Efficient Genome Editing in Livestock
Daniel F. Carlson1, Adrienne L. Watson1, Dennis A. Webster1, Scott C. Fahrenkrug1
1
Recombinetics Inc., St. Paul, Minnesota, USA
Livestock harboring directed genetic compositions have tremendous potential for
improvement of agricultural animals/products, regenerative medicine technologies and
creation of large-animal models for preclinical assessment of therapeutics for safety and
efficacy. A brief overview of editing platforms in livestock will be discussed followed by
three examples where the technology was used to produce three “personalized” animal
models of disease. Dilated cardiomyopathy (DCM) is a major cause of heart failure and a
significant source of mortality and morbidity for children and adults. To create this model,
we have leveraged the discovery of human mutations in RNA Binding Motif 20 (RBM20),
an RNA-splicing protein. Pigs homozygous for the human mutant allele RMB20 R636S
have severe and rapid onset of DCM leading to prototypical heart failure with reduced
ejection fraction and fibrotic myocardium. Heterozygous animals suffer from a more latent
form of disease consistent with heart failure in adult patients. The NF1 pig was developed
by engineering a premature termination codon into minipigs that mimics a common disease
allele in patients. We have observed a striking 100% penetrance of café au lait spots in
these pigs, a phenotype that is seen in patients, but has never been demonstrated in any
other animal model. Fibroblasts isolated from NF1 pigs also show hyperactive Ras activity,
the underlying mechanism of human disease. Progress in characterization of other typical
clinical presentations in NF1 patients will be reported. Complimentary to gene editing,
transposon transgenesis is also a reliable tool for delivery of humanized mutant alleles.
Transgenic Ossabaw expressing a gain-of-function chimp PCSK9transgene have
significantly increased cholesterol (5 to 15-fold, depending on diet) that leads to highly
occlusive, mature atherosclerotic plaques characterized by high levels of inflammation,
calcification and necrosis within the core of the coronary lesions.
Dan Carlson is a “farm kid” from southwestern Minnesota who interest in biotechnology
when his family began planting genetically modified crops in the 90s. He attended the
University of Minnesota where he earned a PhD in animal science with an emphasis in
biotechnology and molecular genetics. The focus of his research is the refinement and
application of methodology for genetic engineering in livestock. Through his 13 years in
biotechnology research, Dan has led the development of transposon systems and gene7

editing technology in livestock. Dan is the vice president of development at Recombinetics
where he directs the application of gene-editing to develop products while continuing to
innovate in the field of genome engineering and develop intellectual property.

Göetz Laible, PhD, AgResearch
S3: Technological Advances Create New Opportunities for the Targeted
Improvement of Livestock
Göetz Laible1, Brigid Brophy1, David Wells1, Sally Cole1, Marion Wright1, Stephanie
Delaney1, Ali Cullum1, Aaron Malthus1, Jingwei Wei1, Stefan Wagner1
1
Animal Science, Reproduction, AgResearch Ruakura, Hamilton, New Zealand
Over millennia humans have modified the genetic makeup of livestock by breeding and
selection strategies to better meet the need for food and other animal products. Although
this strategy has been proven to be highly successful, improvements are generally limited to
incremental steps and typically require the accumulation of small gains over long periods to
realize genuine benefits. The development of transgenic livestock technology now provides
a powerful alternative where it is possible to directly introduce genetic modifications with
known impact and potentially achieve benefits within a single generation. While initially
the technology was held back by technical limitations, these have been largely overcome by
progressive improvements over the past 30 years. In particular, the development of sitespecific nucleases facilitating the efficient and precise editing of livestock genomes makes
it now possible to directly introduce and accumulate favourable alleles in the best animals.
This next generation breeding approach was recently exemplified with the production of
hornless dairy cattle.
Considering the importance of milk as a human food, the rational improvement of milk
composition of dairy animals was one of the earliest goals with the development of
transgenic livestock capabilities. The newly available precision tools create exciting new
options for genetically engineering milk. The presentation will provide an overview about
the humble beginnings and what might be possible now and in the near future to improve
milk for human consumption with these new technologies.
Göetz Laible is a senior scientist at AgResearch, New Zealand’s largest Crown Research
Institute. He holds a PhD in biochemistry from the Free University of Berlin, Germany and
carried out his postdoctoral research at the Salk Institute for Biological Studies in San
Diego. He leads a research program focused on the development and evaluation of genome
modification technologies for future livestock applications.
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Bhanu Telugu, PhD, University of Maryland
S4: Engineering Genomes of Domestic Pigs for Agricultural Applications
Ki-Eun Park1,2, Chi-Hun Park1,2, Anne Powell2, David M. Donovan1,2, Bhanu P. Telugu1,2,*
1
Department of Animal and Avian Sciences, University of Maryland, College Park, MD,
USA; 2Animal Bioscience and Biotechnology Laboratory, USDA, ARS, Beltsville, MD,
USA
The breeding of domestic animals has a longstanding and successful history, starting with
domestication several thousand years ago. Modern animal breeding strategies
predominantly based on population genetics, artificial insemination (AI) and embryo
transfer (ET) technologies have led to significant increases in the performance of domestic
animals, and are the basis for regular supply of high quality animal derived food at
acceptable prices. However, the current strategy of marker-assisted selection and breeding
of animals to introduce novel traits over multiple generations is too pedestrian in
responding to unprecedented challenges such as changing climate, global pandemics, and
feeding an anticipated 33% increase in global population in the next three decades. Here,
we propose site-specific genome editing technologies as a basis for “directed” or “rational
selection” of agricultural traits. These genome editing tools are expected to facilitate
targeted modification of individual traits without affecting the overall genetic merit of the
animal thereby ushering the animal biotechnology into the functional genomics era. The
animal science community envisions these technologies as essential tools in addressing
critical priorities for global food security and environmental sustainability, and strives to
develop these technologies for maximum societal benefit. This work is supported by
funding from NIH-NIFA Dual Purpose with Dual Benefit Grant # 2015-67015-22845.
Bhanu Telugu’s primary appointment is with the University of Maryland, where he is an
assistant professor in the Department of Animal and Avian Sciences. He also holds a
“visiting scientist” appointment with the USDA’s Agricultural Research Service. His
laboratory employs genome-editing tools such as CRISPRs and TALENs for site-specific
alterations of the pig genome for biomedical and agricultural applications.
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Session 2: Modification of Disease Resistance and Susceptibility in Large
Animals
Session Chair - Chris Davies, DVM, PhD, Utah State University, USA
Chris Davies is a research associate professor in the Department of Animal, Dairy and
Veterinary Sciences at Utah State University, director of the university’s Center for
Integrated BioSystems and associate director of the Utah Agricultural Experiment Station.
His research interests include immune responses and gene expression at the maternal- fetal
interface. Additionally he is interested in the identification and characterization of genes
affecting immune function and disease resistance.

Kevin Wells, PhD, University of Missouri
S5: Improved Resistance to Livestock Disease through Genetic Enhancement
Kevin D. Wells1
1
Division of Animal Sciences, University of Missouri, Columbia, MO, USA
It has been more than three decades since genetic engineering (GE) technologies were first
adapted for use in livestock. The earliest attempts to apply GE to agricultural phenotypes
were related to growth. In part, this focus was due to limitations in knowledge of gene
function and the role of genes in physiological phenomena. However, GE efforts soon
expanded to include disease resistance phenotypes. In the first decade of livestock GE,
most of the real success was related to gleaned insight into the design of transgenes.
Examples of health-related transgenes included MX1, specific immunoglobulins, and viral
proteins. However, pronuclear microinjection proved to be inefficient and cost-prohibitive
for many researchers, thus restricting the pace of GE. After the advent of animal cloning via
somatic cell nuclear transfer, the costs of GE animal production was reduced. Among the
first applications of the technology was again disease resistance, specifically, mastitis
resistance. Recently, with the advent of designed nucleases (CRISPR technology in
particular), not only was the cost of entry reduced, but the required skill level was also
reduced. As a result, more groups (commercial and academic) have the capacity to modify
livestock genomes. Since these new genome-editing technologies include the ability to
make small changes that do not introduce transgenes, commercial interests have entered
into the field with the hope of producing agricultural animals with economically viable
phenotypes. This hope spurs from the assumption that small genome changes will be more
acceptable to government regulators and/or the public. Although acceptance of GE in food
animals remains unknown, it is clear that GE technologies have matured to the point that
useful, viable animals can be produced. In addition, there are examples of disease
resistance phenotypes that cannot currently be addressed by any other technology. The
future of animal agriculture may depend entirely on the how regulators react to the very real
benefits that GE livestock present. In addition, genetic engineers need to proceed carefully
as to not select for resistant pathogens or create new pathogen reservoirs.
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Kevin Wells received his PhD in genetics from North Carolina State University. He now
serves as an assistant professor at the University of Missouri with research appointment in
the College of Agriculture, Food and Natural Resources.

Jorge Piedrahita, PhD, North Carolina State University
S6: Development and Characterization of Severe Combine Immune
Deficient Swine
Renan B. Sper & Jorge A. Piedrahita. Comparative Medicine Institute and College of
Veterinary Medicine, North Carolina State University.
The goal of engrafting human cells into other species, in particular hematopoietic stem
cells, has been pursued for six decades. This goal remains and there are multiple labs across
the world that are using, and improving humanized mice to address a range of high impact
biomedical questions. However there is a need for developing systems in species that more
closely resemble humans in size, physiology and longevity. The pig offers an exceptional
and perhaps the best system for this purpose. Pigs are widely available and the life span,
and cell and organ physiology more closely approximates those of human. Pigs are readily
bred, born in litters and amenable to genetic engineering. Additionally, recent advances in
gene editing have allowed the development of complex multi-transgenic pigs at very high
efficiencies. We will describe the development of a IL2RG/RAG1 deficient pig and its
utilization for allogenic and xenogeneic engraftment.
Jorge Piedrahita is a professor in the Department of Molecular Biomedical Sciences in the
College of Veterinary Medicine at North Carolina State University. He is also the director
of the Comparative Medicine Institute, a university-wide center that incorporates over 160
faculty members from 23 different departments and five colleges.

Eddie Sullivan, PhD, SAb Biotherapeutics
S7: The Use of Genetically Engineered Large Animals to Rapidly Respond
to Emerging Infectious Disease through the Production of Therapeutic
Antibodies
Eddie J. Sullivan1, Hua Wu1, Jerry Pommer1, Jin-An Jiao1
SAB Biotherapeutics, Inc., Sioux Falls, SD, USA

1

SAB Biotherapeutics (SAB) has successfully developed a unique transchromosomic (Tc)
bovine platform that can rapidly produce potent, fully human, immunoglobulins against a
variety of disease targets including viruses and bacteria in significant quantities (up to
600g/month/animal of highly purified immunoglobulin). Several forms of passive
immunotherapy to prevent and treat viral infection have and are being studied in animals.
Convalescent plasma have been used in humans, but logistical and production limitations
have prevented widespread use. Additionally, convalescent plasma and specific monoclonal
antibodies to viruses are unlikely to have significant cross-protection efficacy against other
strains. To overcome these limitations, we propose the use of a novel platform to rapidly
produce and deliver high-titer human polyclonal immunoglobulin for treatment and postexposure prophylaxis of viruses and other infectious and toxin-mediated diseases. SAB has
11

developed a Tc bovine in which the bovine immunoglobulin genes have been knocked out
and a human artificial chromosome (HAC) containing the full germ line sequence of human
immunoglobulin has been inserted. Each Tc bovine can produce 150 to 600 grams per
month of purified immunoglobulin and the platform is rapidly scalable. Experimental hightiter immunoglobulins have been rapidly produced against tri-valent seasonal influenza
(pH1N1, H3N2, type B), bi-valent hantavirus (Andes, Sin Nombre), tri-valent alphavirus
(VEE, EEE, WEE), MERS-CoV, and anthrax, among others.
Eddie Sullivan is the president and CEO of SAb Biotherapeutics, a company that produced
the world’s first large animal species that produces fully human polyclonal antibodies.
Eddie has been a thought leader in this field and worked with various committees and
discussion groups that have focused on animal biotechnology and has actively participated
in discussions for establishing a regulatory framework for this technology.
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Session 3: Transgenic Large Animal Models
Session Chair - Carol Keefer, PhD, University of Maryland, USA
Carol Keefer has done pioneering work in the development of in vitro production
techniques in cattle, including in vitro fertilization, intracytoplasmic sperm injection, and
nuclear transfer. She is noted for work that produced the first clone goats using in vitro
transfected donor cells. Dr. Keefer is on the editorial board of Cloning & Stem Cells and is
a past president, vice president and member of the board of governors of the International
Embryo Transfer Society.

Irina Polejaeva, PhD, Utah State University
Ravi Ranjan, MD, PhD, University of Utah
S8: TGF-β1 Transgenic Goat Model of Atrial Fibrillation
Irina A. Polejaeva 1, Ravi Ranjan2, Christopher J. Davies 1, Kenneth L. White 1
1
Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT,
USA; 2 Division of Cardiology, University of Utah, Salt Lake City, UT, USA
Large animal models of progressive atrial fibrosis provide an attractive platform to study
the relationship between structural and electrical remodeling in atrial fibrillation (AF). Here
we established a new transgenic goat model of AF with cardiac specific overexpression of
TGF-β1 and investigated the changes in the cardiac structure and function leading to AF.
Transgenic goats with cardiac specific overexpression of constitutively active TGF-β1 were
generated by somatic cell nuclear transfer. We examined myocardial tissue, ECGs,
echocardiographic data, and AF susceptibility in transgenic and wildtype control goats.
Transgenic goats exhibited a significant increase in fibrosis and myocyte diameter in their
atria compared to controls, but not in their ventricles. P-wave duration was significantly
greater in transgenic animals starting at 12-months of age, but no significant chamber
enlargement was detected, suggesting conduction slowing in the atria. Furthermore, this
transgenic goat model exhibited a significant increase in AF vulnerability. Six of eight
transgenic goats (75%) were susceptible to AF induction and exhibited sustained AF (>2
minutes), whereas, none of six controls displayed sustained AF (P<0.01). Length of induced
AF episodes was also significantly greater in the transgenic group compared to controls
(687±212.02 vs. 2.50±0.88 seconds, P<0.0001).
Marked atrial fibrosis, P-wave prolongation and a significant increase in AF susceptibility
(following a brief electrical induction) are the primary hallmarks of this TGF-β1 transgenic
goat model. In humans, the prevalence of AF increases with age due to atrial substrate
remodeling developing slowly over many decades of life. These transgenic goats for the
first time provide a large animal model where progressive accumulation of fibrosis creates
the basis for developing AF. Serial electrophysiological studies done over time with fibrosis
progression in this model can lead to further mechanistic understanding of AF. We suggest
that these studies will open new clinically relevant mechanism-based targets for the
prevention and treatment of AF.
Irina Polejaeva is an associate professor in the Department of Animal, Dairy and
Veterinary Sciences at Utah State University and a member of Utah Multidisciplinary
Arrhythmia Consortium. Dr. Polejaeva is also a member of the Veterinary Diagnostics and
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Infectious Disease USTAR program. She served for 8 years as chief scientific officer at
ViaGen Inc., led the Cell Biology Group and was project manager for the Porcine Nuclear
Transfer Program at PPL Therapeutics Inc. Her work led to generation of the world’s first
cloned pigs by somatic cell nuclear transfer (SCNT) and the birth of the world’s first 1, 3galactosyltransferase deficient pigs. Her primary emphasis is development of GE large
animal models for biomedical research.
Ravi Ranjan, M.D., Ph.D., is a cardiologist specializing in cardiac electrophysiology. His
clinical interests include ablation of complex cardiac arrhythmias like atrial fibrillation,
ventricular tachycardias and supra-ventricular tachycardias. He also has keen interest in
cardiac device based therapy like cardiac resynchronization therapy, ICDs and pacemakers.
He has been a faculty member at the University of Utah since 2010. He received his
medical degree from Harvard Medical School, completed an internal medicine residency at
Massachusetts General Hospital, Harvard Medical School, a cardiology fellowship at Johns
Hopkins Hospital and a cardiac electrophysiology fellowship at Johns Hopkins Hospital.
Dr. Ranjan has built a large clinical cardiology and electrophysiology practice in Utah.

Randy Prather, PhD, University of Missouri
S9: Development of Animal Models and National Swine Research and
Resource Center
Randall S. Prather, Kevin D. Wells
Division of Animal Sciences, National Swine Resource and Research Center, University of
Missouri, Columbia, MO, USA
There is an urgent need from human medicine, basic biology and production agriculture for
genetically engineered (GE) swine. Human medicine demands models that faithfully
replicate the human condition to develop treatments, and to practice techniques to cure
human aliments. In some cases, swine are by nature appropriate, e.g. cardiovascular
disease, etc. However, in other cases GE makes swine the species of choice for modeling
humans to characterize development and progression of disease, and to develop treatments
and therapies, e.g. cystic fibrosis, diseases of retinal degeneration, etc. A human sized
model is necessary for developing devices, stem cell therapy strategies, and scaling
treatments. Swine are the species of preference for providing organs for xenotransplantation
to humans. The National Institutes of Health (NIH) has considered swine important enough
to their mission of meeting the critical need of models that it established the National Swine
Resource and Research Center (NSRRC). The NSRRC imports models created by others,
curates models (as both live animals and frozen genetics), creates models as requested by
the NIH community, and distributes cells tissues and animals to other not-for-profits.
Applications of GE swine to areas other than medicine are equally justifiable. These range
from understanding basic animal physiology, improving productivity, decreasing inputs,
and changing the carcass composition, to making animals resistant to disease. GE of
domestic pigs can help to address threats to our food security, and improve both
sustainability and animal welfare. One recent example is that of using gene editing to make
pigs resistant to porcine reproductive and respiratory syndrome virus (PRRSV).
PRRSV costs $6M/day in North America and Europe. The potential economic,
sustainability, and animal welfare benefits clearly justify GE swine for applications beyond
resistance to PRRSV. We propose that the United States Department of Agriculture
14

establish a National Agricultural Swine Resource and Research Facility (NASRRF) that
would focus on GE of swine. The NASRRF would respond to agricultural researchers
across the country to provide not only models to better understand basic physiology, but
also to make animals that would address the important issues facing the swine industry.
Clearly, the technology is now advanced to the point where investments need to be made in
GE of swine for both production agriculture and human medicine.
Randy Prather is currently a Curators’ Professor with the title of Distinguished Professor
of Reproductive Biotechnology in the Division of Animal Science at the University of
Missouri. He is also the director of the NIH-funded National Swine Resource and Research
Center. His lab has made over 1000 cloned pigs at MU representing over 45 different
genetic modifications for agriculture and medicine.

Amy Desaulniers, PhD Student, University of Nebraska
S10: Use of Genetically Engineered Swine to Elucidate Testicular Function
in the Boar
Amy T. Desaulniers1, Rebecca A. Cederberg1, Clay A. Lents2 and Brett R. White1
1
Department of Animal Science; University of Nebraska-Lincoln, Lincoln, NE, USA;
2
USDA, ARS, USMARC, Clay Center, NE, USA
The second mammalian GnRH isoform (GnRH-II) and its specific receptor (GnRHR-II) are
highly expressed in the testis. Coding errors prevent their production in many species, but
both genes are functional in swine. We demonstrated that GnRHR-II localizes to porcine
Leydig cells and GnRH-II stimulates testosterone production in vivo, despite negligible
luteinizing hormone (LH) secretion. These data indicate that GnRH-II directly effects
testicular steroidogenesis. To explore this hypothesis, we produced a GnRHR-II
knockdown (KD) swine line. Upon evaluation during pubertal development, testosterone
concentrations were reduced in transgenic compared to littermate control males. However,
LH was unaffected, suggesting that GnRHR-II KD impairs steroidogenesis directly at the
testis rather than inhibiting gonadotropin secretion. Based on these results, our next
objective was to compare diurnal secretory patterns of testosterone in mature transgenic (n
= 5) and littermate control (n = 5) males. Boars were fit with indwelling jugular cannulae
and blood was collected every 15 min for 8 h. Serum testosterone concentrations were
quantified via radioimmunoassay. Next, males were euthanized; testis weight was recorded
and testicular tissue collected to confirm GnRHR-II KD in transgenics via digital droplet
PCR (normalized to β-actin). Results revealed that testosterone was unaffected by time or
line x time interaction (P > 0.05), but a line effect was detected (P = 0.04). Differences were
dramatic; testosterone levels were reduced by 82% in GnRHR-II KD (0.75 ± 0.05 ng/ml)
compared to control (4.09 ± 0.29 ng/ml) males. Despite divergent testosterone
concentrations, testis weights were similar between lines (P > 0.05), suggesting diminished
Leydig cell function versus hypotrophy/hypoplasia. Since testicular GnRHR-II mRNA
levels were reduced by 69% in transgenics (P < 0.001), these data demonstrate that GnRHII and its receptor play a critical role in testosterone biosynthesis within porcine Leydig
cells. Given that testosterone and its metabolites dictate male reproductive success, GnRHII and its receptor represent unique targets to improve boar fertility. Notably, these swine
represent the first genetically engineered animal model to examine the role of GnRH-II and
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its receptor in mammals. Supported by NIFA Hatch (NEB-26-199; BRW) and AFRI (201167015; CAL) funds. USDA is an equal opportunity provider and employer.

Seon-Ung Hwang, Chungbuk National University, Korea
S11: Production of Transgenic Pigs with pGFAP-CreERT2; EGFPLoxP
Inducible System
Seon-Ung Hwang1,2, Junchul David Yoon1,2, Kiyoung Eun3, Hyunggee Kim3,* and SangHwan Hyun1,2*
1
Laboratory of Veterinary Embryology and Biotechnology, Veterinary Medical Center and
College of Veterinary Medicine, Chungbuk National University, 1 Chungdae-ro, Seowongu, Cheongju 28644, Republic of Korea;
2
Institute of Stem Cell & Regenerative Medicine, Chungbuk National University, 1
Chungdae-ro, Seowon-gu, Cheongju 28644, Republic of Korea;
³
Department of Biotechnology, School of Life Sciences and Biotechnology, Korea
University, Seoul 02841, Republic of Korea.
Transgenic (TG) pigs are currently believed to be an important model for biomedical
research, including for disease models, pharmaceutical toxicity testing and regenerative
medicine. In the present studies, we constructed two vector systems using pGFAP
promoter; one retains pGFAP promoter-CreERT2 transgene and the other has enhanced
green fluorescent protein (EGFP) gene flanked by LoxP sites which can be eliminated
through the CreERT2-mediated recombination. We also established donor transgenic pig
fibroblasts with pGFAP-CreERT2+LCMV-EGFPLoxP for somatic cell nuclear transfer
(SCNT). Then, to produce TG pigs with pGFAP-CreERT2; LCMV-EGFPLoxP transgene
constructs, embryo transfer was performed three times just before ovulation state of the
surrogate mothers. One of them was pregnant, and delivered five TG pigs at 115 days after
pregnancy. Polymerase chain reaction (PCR) analysis with genomic DNA prepared from
skin tissues of TG pigs revealed that all five TG pigs had transgenes. In addition, EGFP
expression in all organs tested was confirmed by autopsy and PCR. The real-time PCR
analysis showed that pGFAP promoter-driven CreERT2 mRNA was highly expressed in
the cerebrum. Three months after birth, TG pig was orally administrated with 15 mg/kg of
4-hydroxytamoxifen (TM) during 5 days, and then euthanized after 7 days. Semi-nested
PCR analysis with genomic DNA revealed that the CreERT2–mediated recombination was
induced in the cerebrum and cerebellum, but not skin. Taken altogether, we generated TG
pig with TM-inducible pGFAP-CreERT2; EGFPLoxP recombination system by SCNT. The
current study is the first report of the astrocyte-specific pGFAP-CreERT2 inducible system
in TG pigs. Therefore, we suggest that this technology will be a useful tool for studying
physiology of astrocytes and generatingTG pig model of CNS diseases such as
Huntington’s disease, Alzheimer’s disease and brain tumor. Keywords: Porcine, SCNT,
CreERT2 system, GFAP This work was supported, in part, by a grant from the
"Cooperative Research Program for Agriculture Science & Technology Development
(Project No. PJ011288, PJ011077)" Rural Development Administration, and the "National
Research Foundation of Korea Grant funded by the Korean Government (NRF2013R1A2A2A04008751)", and the "Ministry of Trade, Industry & Energy(MOTIE),
Korea Institute for Advancement of Technology(KIAT) through the Leading Industry
Development for Economic Region (Project No. R0004357)", Republic of Korea.
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Session 4: Regulation of Genetically Engineered Large Animal Models and
Medical Device Development Tools, Presentations and Panel Discussion

Moderator - Mark Walton, PhD, Yorktown Technologies, LP, USA
Mark Walton is a veteran of the plant and animal biotechnology industries. He has worked
as a research scientist, entrepreneur and corporate executive. In 2016 he joined Yorktown
Technologies, LP, the developer of GloFish Fluorescent Fish, to lead a new division,
Ornamental Bio. Previously he was the chief marketing officer for Recombinetics.
Dr. Walton played a key role in obtaining the Cloning Risk Assessment and the Guidance
on Regulation of Genetically Engineered Animals from the U.S. Food and Drug
Administration.

Malini Wileman, PhD, Biologist, Center for Veterinary Medicine, FDA, USA
Dr. Wileman (née Mansharamani) is a highly skilled regulatory reviewer with technical
expertise in cell and molecular biology, biochemistry, and biotechnology. She draws on her
9 years of combined regulatory experience in human and animal biologics development and
manufacture as the lead scientist at the Center for Veterinary Medicine at the FDA, for
several technical and policy-making issues, particularly emerging technologies, biopharm
animal production, and inter-center collaboration and review. Dr. Wileman obtained her
PhD in Biomedical Sciences from the Texas Tech University Health Sciences Center. After
completion of her post-doctoral research at the Johns Hopkins School of Medicine in
Baltimore, MD, Dr. Wileman worked in biologics manufacturing and process validation at
BioReliance, and joined the FDA in 2009.

Donna Lochner, Senior Scientific Advisor, Center for Devices and
Radiological Health, FDA, USA
Donna Lochner is associate director of the Office of Science and Engineering Laboratories
at the FDA where she manages regulatory science initiatives. Prior to her current position,
she was deputy director of the FDA’s Division of Cardiovascular Devices and chief of
FDA’s Intraocular and Corneal Implants Branch. Before joining the FDA, Donna worked
for Cordis Corporation. She earned a degree in chemical engineering from the Pennsylvania
State University.

Laura Epstein, Senior Analyst, Center for Veterinary Medicine, FDA, USA
As a senior policy analyst for the U.S. Food and Drug Administration’s Center for
Veterinary Medicine (CVM), Laura Epstein analyzes proposed policies and evaluates the
effects of existing ones in order to help the FDA make informed decisions and achieve the
center’s mission to protect human and animal health. The CVM approves animal drugs and
monitors their safety and efficacy for companion and food-producing animals.
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Jill Ascher, DVM, MPH, Deputy Director, Division of Veterinary Services,
Center for Biologics Evaluation and Research, FDA, USA
As deputy director of the Division of Veterinary Sciences at the FDA, Dr. Ascher
participates in planning, managing, organizing and directing activities of the division to
safeguard animal welfare by providing exceptional veterinary care throughout the animal
program. She is committed to protecting and improving public health, and ensuring the
safety and effectiveness of new drugs through support of regulatory sciences research.
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Session 5: Current and Future Large Animal Models in Biomedical
Research
Session Chair - Zhongde Wang, PhD, Utah State University, USA
Dr. Zhongde Wang is an associate professor in the Department of Animal, Dairy and
Veterinary Sciences at Utah State University. In addition to his academic appointment,
Dr. Wang is also the president, chief scientific officer and co-founder of Auratus Bio, a
biotech company specialized in animal genetic engineering. Dr. Wang’s research team
employs modern genome engineering tools (such as CRISPR/Cas9, TALEN and piggyBac
transposons) and assisted reproduction technologies (such as somatic cell nuclear transfer
or cloning) to create genetically engineered animal models of human diseases. The Wang
laboratory is the first to succeed in developing gene-targeting tools in the golden Syrian
hamster. Dr. Wang received his Ph.D. degree in molecular and cellular biology from
University of Massachusetts at Amherst in 2000 and did his postdoctoral trainings at
Massachusetts Institute of Technology.

David Ayares, PhD, Revivicor Inc., USA
S12: Genetically Engineered Pigs for Xenotransplantation
David Ayares1, Todd Vaught1, Suyapa Ball1, Jeff Monahan1, Kasinath Kuravi1, Ben
Morrill1, Amy Dandro1, Anneke Walters1, Steven Butler1, Lori Sorrells1, Kent Adams1,
Maria Kokkinaki1, Jagdeece Ramsoondar1, John Bianchi1, and Carol Phelps1
1
Revivicor Inc, Blacksburg, Virginia, USA (a subsidiary of United Therapeutics)
Genetic modification of the genome of pigs offers the opportunity to provide an unlimited
supply of human-compatible xenograft donor organs, cells, and tissues for transplantation.
Editing nucleases such as CRISPR/Cas9, combined with homology-driven recombination
make gene knockout or knockin seem routine. Knockout of the α1,3-galactosyl transferase
gene (GTKO) resulted in the elimination of hyperacute rejection (HAR), and prolonged
survival of xenografts in non-human primate studies. Employing a combination of cloning
and breeding, next-generation GTKO pigs were produced with constitutive high-level
expression of the complement regulatory genes, hCD46 and hDAF, that demonstrated
strong inhibition of complement mediated cell lysis, while in vivo studies in non-human
primates with islets and whole organs showed prolonged survival and function (over 6mo.
for both islets and hearts) in the absence of antibody-mediated rejection. In order to
overcome molecular incompatibilities in clotting factors between donor and recipients,
human transgenes for inhibition of coagulation and thrombosis, including TFPI,
thrombomodulin (TBM), EPCR and CD39, under endothelial cell-specific promoter
systems, were added alone or in combination to produce donor pigs. Hearts from
GTKO/hCD46/TBM transgenic pigs transplanted into baboons have maintained function
for 900+ days, (with two others exceeding 1 year), demonstrating significant efficacy of
these pig organ xenografts. In addition, towards prevention of cell mediated rejection with
reduced immuno-suppression, source pigs were produced which overexpress a dominantnegative inhibitor of SLA class II (CIITA-DN), as well as genes to provide cytoprotection
(HO-1 and A20), and immunomodulation (CD47). Multi-cistronic “2A” vectors have
facilitated the production of transgenic pigs with more than six genetic modifications,
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where the added genes are not only co-expressed, but co-integrated in the genome, thus
allowing propagation of new lines with reduced transgene segregation. Tissues, cells, and
organs from these multi-transgenic pigs have the potential to address virtually all levels of
xenograft incompatibility, and should help drive outcomes that justify initiation of human
clinical trials.
David Ayares is executive vice president and chief scientific officer for Revivicor Inc. and
leader of the team that cloned the world’s first pigs. Revivicor is a regenerative medicine
company focused on a diverse pipeline of genetically engineered pigs as an alternative
source of organs and tissues for human therapeutic use. Dr. Ayares was previously vice
president of research and COO for PPL Therapeutics, and he worked for seven years in the
pharmaceutical industry at Abbott Laboratories and Baxter Healthcare, developing
transgenic mouse models for pharmaceuticals testing.

Michael Cutler, DO, PhD, Intermountain Heart Institute
S13: Translational Cardiovascular Research Utilizing Large Animal
Genetic Engineering
Michael J Cutler, DO, PhD1
1
Intermountain Medical Center Heart Institute, Intermountain Medical Center,
Murray, Utah, USA
Cardiovascular disease is the #1 cause of death worldwide and is a major public health
problem. Understanding the underlying mechanisms of cardiovascular disease is
paramount to developing new and improved therapies to reduce the incidence of
cardiovascular disease-related deaths. Significant advances have been made in our
understanding of the cellular and molecular mechanisms of many aspects of cardiovascular
disease using genetically altered small animal models. However, there are important
limitations to translating these research findings to human medicine. This presentation will
discuss the limitations of current small animal models and the potential benefits of large
animal genetic engineering in advancing our understanding of the cellular and molecular
mechanisms of cardiovascular disease. In particular, there will be special emphasis on the
role of large animal genetic engineering in advancing these mechanistic insights into
clinically meaningful therapies in humans.
Michael Cutler is a heart rhythm specialist at the Intermountain Heart Institute and was
previously an assistant professor of medicine at Case Western Reserve University. His
research interests include understanding the cellular and molecular mechanisms of cardiac
arrhythmia and gene therapy for cardiac arrhythmias. Dr. Cutler has received recognition
from the American Physiological Society, American Heart Association and the Heart
Rhythm Society for his work.
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Chris Rogers, PhD, Exemplar Genetics
S14: TP53 and KRAS Targeted Pigs: A Platform for Models of Human Cancer
Dawn Quelle1, Jessica Sieren2, David Meyerholz3, Benjamin Darbro4, Mahmoud Abou
Alaiwa5, Carlos Chan6, and Christopher S. Rogers7
1
Department of Pharmacology, University of Iowa, Iowa City, IA, USA; 2 Department of
Radiology, University of Iowa, Iowa City, IA, USA; 3 Department of Pathology, University
of Iowa, Iowa City, IA, USA; 4 Department of Pediatrics, University of Iowa, Iowa City,
IA, USA; 5 Department of Internal Medicine, University of Iowa, Iowa City, IA, USA; 6
Department of Surgery, University of Iowa, Iowa City, IA, USA; 7 Exemplar Genetics,
Coralville, IA, USA
We recently developed Yucatan miniature pigs with targeted TP53 mutations. Initial
characterization reveals that 100% of TP53R167H/R167H mutant pigs develop cancer.
These homozygous TP53 mutant pigs express two mutant alleles (R167H) of the p53 tumor
suppressor in all tissues and are an outstanding model of osteosarcoma and B-cell
lymphoma; however, the animals die from those tumors before other cancers can develop.
By comparison, heterozygous TP53R167H/+ pigs are tumor-free after more than 2.5 years
of age, though they are likely ‘primed’ for tumor development if other cancer genes are
concomitantly altered. Our objective is to generate and characterize porcine cancer models
in which tumorigenesis can be conditionally induced in specific tissues. We are particularly
interested in lung and pancreatic cancers since they are among the deadliest and most
difficult to diagnose malignancies in humans. A majority of human lung and pancreatic
tumors are defined by the combined activation of oncogenic KRASand inactivating
mutations of TP53 (typically on just one allele). Mouse models that replicate those genetic
events by conditionally expressing TP53 and KRAS mutations in the lung or pancreas
effectively develop cancers in those tissues. While informative, such small animal tumor
models possess significant limitations and challenges for translational oncology. Large
animals, such as pigs, share greater similarities with humans in anatomy, physiology,
genetics, lifespan, and importantly, size. Therefore, we created dual targeted
KRASG12D/+/TP53R167H/+ pigs which express one mutant allele of the TP53 gene as
well as Cre-inducible mutant KRAS. We hypothesize that these conditional KRAS/TP53
mutant pigs will produce site-specific cancers, as seen in comparable mouse models,
providing much needed large animal tumor models for translational imaging, biomarker
discovery, and pre-clinical testing of novel anticancer therapies. Studies are currently
underway to establish the utility of the conditional KRASG12D/+/TP53R167H/+ pig model
by defining optimal conditions for mutant KRAS induction and tumor development in the
lung and pancreas.
Chris Rogers is the chief scientific officer and co-founder of Exemplar Genetics, a
company focused on the development and study of improved models of human disease.
Dr. Rogers received his PhD from Vanderbilt University and completed post-doctoral
training at the University of Iowa. While at Iowa, Dr. Rogers and colleagues created the
first knockout and knockin models of a human disease in a large animal species - cystic
fibrosis in pigs. At Exemplar Genetics, Dr. Rogers has directed the development and
characterization of additional disease models including cancer, neurodegenerative disorders
and cardiovascular diseases.
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Timothy Sheets, PhD Student, University of Maryland
S15: Investigating the Conserved Role of Neurogenin 3 (NGN3) in Endocrine
Pancreatic Development in the Porcine Model Using CRISPR/Cas9 System
Timothy P. Sheets1,2, Ki-Eun Park1,2, Anne Powell2, Steven Swift2, David M. Donovan2,
Bhanu Telugu1,2
1

Department of Animal and Avian Sciences, University of Maryland-College Park, MD.
USA
2
Agricultural Research Services, Animal Bioscience and Biotechnology Laboratory,
USDA, Beltsville, MD. USA
The domestic pig is important as an agricultural and biomedical model species. The pig can
serve as a complement to current mouse models, and in many cases, replace the mouse
completely as a model for human disease. A failure to translate data generated from the
mouse into human clinical trials limits the use of this model moving forward. The domestic
pig is currently used in the medical device industry and by drug companies, due to its
similar organ and vessel size to humans and the ability to model Adsorption Distribution,
Metabolism and Excretion (ADME) studies. In the age of genome engineering and targeted
gene therapy, the pig, can provide a longer life expectancy for disease progression, long
term phenotypes and treatment end points. Using an example of ongoing disease modeling,
the CFTR pig model not only surpasses the mouse models in comparative primary lung
phenotype, but also recapitulates secondary phenotypes, specifically pancreatic agenesis
leading to diabetes. In this study, we investigated whether the role of NGN3 is conserved
across species. NGN3 is a member of the basic helix-loop-helix transcription factor family.
In the mouse, Ngn 3 is both necessary and sufficient for the formation of endocrine
pancreas during development. NGN3 is also believed to function in human endocrine
pancreas development. In this study, we identified and amplified NGN3 from porcine BAC
libraries. Once assembled, we designed guides to specifically target genomic sequence of
NGN3 in the domestic pig for generating a knock-out. We injected a pre-complexed
CRISPR/Cas9 protein and a NGN3-targeting sgRNA into porcine in vivo derived embryos;
which were then transferred into synchronized surrogate animals. At day 63 of pregnancy, 9
fetuses were harvested for genotypic and phenotypic analysis. Out of 9 piglets, 5 of them
had biallelic mutations across the target site. RT-PCR data show loss of downstream genes
in 3 of the biallelic mutants. Currently, we are confirming these data with IHC. Once the
role of NGN3 is confirmed, we will investigate its role in transdifferentiation, converting
exocrine cells to an endocrine lineage, and evaluate their efficacy in vitro and in vivo.
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S16: Introduction of Callipyge Mutation into the Goat Genome Using
Transcription Activator-like Effector Nucleases (TALENs)
Min Yang1†, Dennis Webster2†, Qinggang Meng1, Zhiqiang Fan1, Daniel Carlson2, Misha
Regouski1, Tracy Hadfield1, Christopher Bidwell3, Scott Fahrenkrug2, Noelle Cockett1 and
Irina Polejaeva1
1
Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT,
USA; 2 Recombinetics, Inc., Saint Paul, MN, USA; 3 Department of Animal Sciences,
Purdue University, West Lafayette, IN, USA † Equal contribution
The callipyge (CLPG) mutation arose in sheep in the 1980s with a phenotype of muscle
hypertrophy and a novel inheritance mechanism of polar overdominance. The mutation is a
single base, A to G transition, located within DLK1-DIO3 imprinted gene cluster. The
regulatory mutation increases expression of several genes within the cluster. The aim of this
study was to transfer the CLPG mutation into goats using TALENs and somatic cell nuclear
transfer (SCNT). The desired adenine to guanine base change was introduced by
co-transfection of TALENs and a single-stranded oligonucleotide was utilized as a template
for homology directed repair. This strategy enabled production of homozygous and
heterozygous cell clones for SCNT. CLPG cells were transferred into enucleated oocytes.
Fused embryos were then activated for 5 min in 5 µM ionomycin followed by 4 h in 2mM
DMAP with 5 µg/ml cycloheximide, cultured overnight and transferred into the oviducts of
synchronized recipients. In total, 348 one-cell stage embryos were transferred to 21
recipient goats. Three pregnancies went to term and four male offspring that carried
homozygous CLPG alleles were produced. These goats would not be expected to exhibit
muscle hypertrophy but may have altered gene expression. Biopsies of the longissimus
dorsi were used to assess gene expression in the DLK1-DIO3 cluster (4 clones and 6
age-matched controls). Gene expression was assayed for five loci (DLK1, CLPG1 and three
maternal expressed long ncRNA) using RT-qPCR. There were no significant differences in
gene expression between clones and controls. However, two clones had greater than 2-fold
increase in the MEG3 levels and the other two clones had greater than 2-fold increased
levels of DLK1 and much larger increases in CLPG1. The high variability in gene
expression among the clones is likely due to incomplete reprogramming often observed
following SCNT. These results demonstrate that TALENs and SCNT technologies can be
efficiently used to introduce point mutations in goats. The muscle hypertrophy phenotype
and regulatory effects of the goat CLPG allele will be tested by paternal transmission of the
nascent allele to F1 progeny.
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Session 6: Funding Mechanisms to Support Genetically Engineered
Livestock Research, Presentations and Panel Discussion
Moderator - Ken White, PhD, Utah State University, USA
Ravi Ravindranath, DVM, PhD, NICHD, National Institutes of Health, USA
Ravi Ravindranath is director of the Preimplantation Genetics and Development Program in
the National Institutes of Health’s Reproductive Sciences Branch. He is responsible for
grants related to oocytes, sperm, fertilization, preimplantation embryo development,
embryonic stem cells, and germ cell development. His portfolio also includes grants related
to cloning and reprogramming, preimplantation genetic diagnosis and Assisted
Reproductive Technologies (ART). Following his doctorate in veterinary medicine and a
M.S. in microbiology, Ravi earned a PhD in biochemistry from the Indian Institute of
Science. He completed postdoctoral training at the University of Pittsburgh and the Clinical
Research Institute of Montreal, Canada, before joining the Department of Anatomy and
Cell Biology faculty at the Georgetown University Medical Center, Washington, D.C. He
was an adjunct scientist in the Laboratory of Clinical and Developmental Genomics at the
National Institute of Child Health and Human Development. His research background is in
reproductive biology and endocrinology of rodents and nonhuman primates.

Adele Turzillo, PhD, Director, Division of Animal Systems, USDA National
Institute of Food and Agriculture, USA
Adele provides leadership in the development, evaluation and management of a broad range
of programs in research, extension and education. She is a primary point of contact for
issues related to livestock production and serves as liaison to academia, the states, and
several multistate projects. Adele also interacts with other federal agencies and serves as a
scientific advisor on matters related to animal agriculture.

Miguel Contreras, PhD, Program Officer, Division of Comparative Medicine,
Office of Research Infrastructure Programs, National Institutes of Health, USA
Miguel Contreras is a program officer with the Division of Comparative Medicine, Office
of Research Infrastructure Programs, located within the Division of Program Coordination,
Planning, and Strategic Initiatives, National Institutes of Health Office of the Director. He
manages a research resource grant portfolio that includes aquatic and mammalian models
and is program coordinator for the SBIR/STTR Small Business program. He is a biochemist
at the Universidad de Concepcion, Concepcion, Chile. He received his PhD in molecular
and cellular biology and pathobiology from the Medical University of South Carolina
(MUSC), in Charleston. He was a Fogarty International Fellow at the Laboratory of
Neurosciences, National Institute on Aging, NIH, in Bethesda, MD. Prior to joining ORIP,
he was an assistant professor at the Charles Darby Children’s Research Institute and the
Department of Pediatrics, College of Medicine, of the MUSC. His research focused on the
mechanism of degeneration of the nervous system’s white matter in inherited metabolic
disorders that affect peroxisomes and lysosomes (X-linked Adrenoleukodystrophy, Globoid
cell leukodystrophy).
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Session 7: Current and Future Large Animal Models in Biomedical
Research
Session Chair - Jon Oatley, PhD, Washington State University, USA
Dr. Oatley’s studies the regulation of germline cell fate decisions in mammalian testis. His
current research focus is on investigating the role of basic helix-loop-helix (bHLH) proteins
in controlling spermatogonial stem cell fate decisions, the influence of non-coding small
RNAs on establishment of the spermatogonial stem cell pool, and identifying growth
factors produced by testis somatic support cell populations that contribute to the niche
microenvironment. He directs Washington State University’s Center for Reproductive
Biology.

Eckhard Wolf, PhD, University of Munich Gene Center
S17: Genetically Tailored Pig Models for Translational Diabetes Research
Eckhard Wolf1,2, Andreas Blutke3, Rüdiger Wanke3, Simone Renner1,2
1

Gene Center and Center for Innovative Medical Models (CiMM), LMU Munich, Munich,
Germany
2
German Center for Diabetes Research (DZD), Neuherberg, Germany
3
Institute of Veterinary Pathology, Center for Clinical Veterinary Medicine, LMU Munich,
Munich, Germany
Diabetes mellitus (DM) has emerged into a steadily increasing health problem and the
predicted future dimension of the global DM epidemic is alarming. Thus concerted research
efforts are imperative to gain insight into disease mechanisms and to develop preventive
and therapeutic strategies. Diabetic rodent models have limitations for translational
research. Genetically engineered pig models may help to bridge the gap between basic
research and clinical studies in (pre)diabetic patients (reviewed in [1]).
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagonlike peptide-1 (GLP1) are secreted by enteroendocrine cells upon nutrient ingestion and
stimulate insulin secretion. In type 2 diabetic patients the insulinotropic action of GIP is
markedly reduced. To mimic this disturbance in a large animal model, we generated
transgenic pigs expressing a dominant-negative GIP receptor (GIPRdn) under the control of
rat Ins2 promoter sequences in the pancreatic islets (reviewed in [2]). GIPRdn transgenic
pigs exhibit an impaired incretin effect due to a blunted insulinotropic action of GIP, a
progressive deterioration of glucose control due to delayed and – at later stages –
quantitatively reduced insulin secretion, and an impairment of physiological age-related
expansion of beta-cell volume [3]. GIPRdn transgenic pigs thus provide a unique
opportunity to screen for biomarker candidates during the pre-diabetic period [4] and to test
therapeutic strategies targeting the GLP1 receptor [5].
Missense mutations in the INS gene have been identified as common cause of insulindeficient, permanent neonatal diabetes mellitus in humans, also referred to as mutant INS
gene-induced diabetes of youth (MIDY). We produced a transgenic MIDY pig line
expressing INSC94Y under the control of the porcine INS promoter. MIDY pigs show
early-onset clinical diabetes mellitus, markedly reduced body weight gain and beta-cell
volume associated with a marked reduction of insulin secretory granules and severe dilation
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of the endoplasmic reticulum in the beta-cells [6]. MIDY pigs can be used for insulin
treatment studies or for testing the efficacy of gene or cell therapies as well as islet
transplantation. Secondary lesions of diabetes mellitus are another interesting area of
research. We thus established the Munich MIDY pig biobank (highlighted in [7]) as a
unique resource for studying systemic consequences of chronic hyperglycemia.
References: [1] Renner et al., Theriogenology 86, 406-21 (2016); [2] Renner et al., J Pathol
238, 345-58 (2016); [3] Renner et al., Diabetes 59, 1228-38 (2010); [4] Renner et al.,
Diabetes 61, 2166-75 (2012); [5] Streckel et al., J Transl Med 13, 73 (2015); [6] Renner et
al., Diabetes 62, 1505-11 (2013); [7] Abbott, Nature 519, 397-8 (2015).
Funding: German Center for Diabetes Research (DZD); German Research Council
(Transregional Collaborative Research Center 127).
Eckhard Wolf is director of the Laboratory for Functional Genome Analysis. He is the
director of the Center for Innovative Medical Models, a member of the German National
Academy of Sciences and corresponding member of the Austrian Academy of Sciences.
Dr. Wolf is a leading specialist in the development of tailored animal models for
translational biomedical research.

Ann Harris, PhD, Feinberg School of Medicine, Northwestern University
S18: Why Might New Large Animal Models of Cystic Fibrosis be Useful for
Generating New Therapies?
Ann Harris, PhD, Dept. Pediatrics and Lurie Children’s Research Center, Northwestern
University, Chicago, IL. USA
There are now many animal models of the common, inherited disorder cystic fibrosis (CF).
These include multiple mouse strains, with various human pathogenic mutations on
different genetic backgrounds; a rat; ferrets; rabbits and several mutant pig lines. Each of
these models recapitulates some aspects of the human disease, but none accurately
reproduces the complete human phenotype. Severity of disease in CF pigs, the most similar
model to humans, presents additional challenges. These limitations are particularly relevant
when considering the testing of new therapeutic strategies. Here we consider what
additional models could advance understanding of the CF phenotype and how they might
contribute to attempts to find a cure for CF.
Ann Harris is a professor in pediatrics and human molecular genetics at the Feinberg
School of Medicine. Her primary research interest is elucidation of the regulatory
mechanisms for the cystic fibrosis transmembrane conductance regulator (CFTR) gene,
which when mutated causes the devastating inherited disease cystic fibrosis.
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Noelle Cockett, PhD, Utah State University
S19: Future Perspectives for Genetic Editing of Large Animals
Noelle E. Cockett1
1
Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT
84322-1435 USA
Opportunities for genetic editing in livestock exist in the areas of large animal biomedical
models and improvement of livestock production. While the generation of genetic edited
animals is fairly straight forward, both areas are impeded by onerous regulatory processes
that govern genetically modified animals. These regulations are primarily focused on the
perceived dangers of consuming end products such as milk or meat of a genetically
modified animal. Although large animals used as biomedical models are not intended for
human consumption, the current regulations require containment to prevent the animal from
moving into the food chain. In contrast, genetically edited production animals are intended
for human consumption but pose no more risk to the consumer than any other production
animals. In some cases, because of the genetic edit, animals will require less antibiotics
and/or have reduced welfare issues, which are desirable outcomes for consumers.
Given the innocuous methods that now exist for genetic editing, the focus of regulation
should move from the process of generating the animal to a review of the resulting animal.
Refocusing regulation requirements will substantially reduce the cost of genetically edited
animals. However, an additional cost is added to the large animal biomedical model, which
is the need for the model to be validated using a collection of clinical phenotype
measurements. It is unlikely that researchers will use a large animal model without that
validation.
Noelle Cockett currently serves as Utah State University’s executive vice president and
provost, and is a professor in the Department of Animal, Dairy and Veterinary Sciences.
She has built a career in sheep genetics research, specializing in molecular genetics and
identifying genetic markers. Dr. Cockett is known for being part of the research team that
successfully sequenced the ovine genome.
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P1: A Simple and Efficient Vitrification Procedure for Cryopreserving Mouse Embryos and
Oocytes Using Plastic Semen Straws
Mo Guan, Martin Fray
Medical Research Council, Mary Lyon Centre, Harwell Campus, Oxfordshire, OX11 0RD, UK
Vitrification is a freezing method in which cells and media are solidified without ice crystal
formation. Consequently, injuries related to ice formation are less likely to occur. To achieve
success in vitrification, high cooling rates and high concentrations of solutes are commonly
believed to be necessary. However, to reduce the toxicity of the vitrification solutions and to
achieve a high cooling rate, a minimum time in the vitrification solution and a minimum volume
of vitrification solution are thought to be essential. However, these requirements make
embryo/oocyte handling difficult during the vitrification, and subsequent warming procedures.
Compared with other vitrification methods, the DAP213 vitrification method is simple and
efficient, and only requires a brief two-step exposure of embryos/oocytes to the vitrification
solution prior to plunging directly into liquid nitrogen. However, this method has traditionally
used a specific type of vial as the sample carrier, which is not compatible with many laboratories
which use plastic semen straws as their preferred storage system.
At the MRC we have developed an aluminium cooling plate for vitrification in straws. The
cooling plate ensures stable refrigeration at 0°C during the equilibration process. In the
experiments reported here, 2-cell embryos from C57BL/6N Tac mice were used. For
comparison, embryos were vitrified in straws (n=3) and vials (n=3) using DAP213 as
vitrification solution. The viability of vitrified embryos was compared in terms of post-warming
survival rate, as well as their in vitro and in vivo developmental rates. The results demonstrated
that there is no significant difference between straws and vials in survival rate (97.14 ± 2.86 vs
98.10 ± 0.95), development to blastocyst (94.74 ± 2.90 vs 84.48 ± 6.16) and birth rate (43.33 vs
46.67). These results indicated that the DAP213 vitrification procedure can be adapted for use
with straws which are cheap to buy and compatible with space saving bulk tank storage systems.
This method can also be used for oocytes vitrification.
Keywords: vitrification, mice, embryo, oocyte

P2: Derivation of Extra-Embryonic Endoderm Cells from Preimplantation Pig Blastocysts
Chi-Hun Park1,2, Anne Powell2, David M. Donovan2, Bhanu P. Telugu1,2
1
Department of Animal and Avian Sciences, University of Maryland, College Park, MD,
USA; 2Animal Bioscience and Biotechnology Laboratory, USDA-ARS, Beltsville, MD, USA
In the fertilized mammalian embryo, the development of blastocyst marks the first visual cell
fate decision. In the blastocyst, the precursor cells for placental extraembryonic membranes
called the trophectoderm (TE) line the outside of the embryo, whereas, the cells on the inside
aptly called the inner cell mass (ICM) give rise to the fetus proper. Following this first lineage
differentiation event, a group of cells from the ICM also give rise to the primitive endoderm cells
(PrE) that line the inside of the fluid filled blastocoel cavity forming the yolk sac. In culture, the
blastocyst stage embryos give rise to characteristic lines derived from the TE, ICM and PrE.
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Here we describe the establishment and characterization of extraembryonic endoderm (XEN)
cell lines derived from PrE of day 7 pre-implantation pig blastocysts. In vitro generated porcine
D7 blastocysts were explanted onto irradiated mouse embryonic fibroblasts in DMEM medium
supplemented with 15% fetal calf serum (FCS), leukemia inhibitory factor (LIF), and basic
fibroblast growth factor (bFGF). After 2 days of culture, three types of cell outgrowths as
evidenced by morphology and the expression of lineage-specific markers were identified. A
cluster of cells with compact morphology and likely derived from the epiblast (Epi) expressed
key pluripotent markers (e.g. NANOG, and SOX2), whereas the other two cell types that
exhibited a cobble-stone morphology expressed markers of TE-specific genes (CDX2) or PrE(GATA4 and GATA6). Following initial establishment, Epi and TE cells have mostly
disappeared during further subculture, whereas XEN cell colonies expressing GATA factors
grew rapidly and were continuously cultured for over 30 passages. These cells showed high level
of SALL4 expression, which contributes to the regulation of stemness of XEN cells, but not
AFP, which is a visceral endoderm marker. Its proliferation was dependent on feeder cells with
either LIF or FGF signal molecules. In summary, we demonstrated that the XEN cell lines from
day 7 pig blastocysts can be reproducibly derived and the morphological and molecular
characteristics of these cells are similar to mouse XEN cells. However, further studies are needed
to determine whether pig XEN cells fulfill the requirement of typical XEN cells features.

P3: Disruption of CFTR Gene in Sheep Fibroblast Cells Using CRISPR/Cas9 Approach
Zhiqiang Fan1, Zhongde Wang1, Iuri V. Périssé1, Min Yang1, Misha Regouski1, Ann Harris2,
Kenneth L. White1, Irina A. Polejaeva1
1
Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan,
UT 84322, USA; 2 Department of Pediatrics, Northwestern University Feinberg School of
Medicine, Chicago, IL 60614, USA.
Cystic Fibrosis (CF) is a common life-shortening, autosomal recessive disease in Caucasian
populations that affects approximate 1 of every 2500 newborns. The CF gene was identified as
the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) encoding a conductance
chloride anion channel. Sequence analysis of CFTR shows 90% similarity at the nucleic acid
level and 95% at the polypeptide level between sheep and human. A sheep model of CF is likely
to be beneficial in investigating CF pathogenesis and furthering pharmacological approaches to
the treatment of CF. Here, we report the successful application of the CRISPR/Cas9 system to
disrupt CFTR in sheep fibroblast cells, which can be used for the production of cloned sheep by
Somatic Cell Nuclear Transfer (SCNT). We designed 5 single-guide RNAs (sgRNAs) specific
for CFTR: 2 for exon 2 and 3 for exon 11. The targeting vectors were constructed by using
pX330 plasmid and transfected into 2 x105 male fetal fibroblast cells. The gene mutation
efficiency of each targeting vector was determined by PCR/RFLP assay 3 days post transfection.
Our results showed that 2 sgRNAs, 5’- GAAAGGATACAGACAGCGCT – 3’ for exon 2 and 5’
–GGGAGAATTGGAACCTTCAG – 3’ for exon 11, were highly efficient in directing Cas9 to
generate targeted cleavages in CFTR, with mutation efficiencies of 18.5 % and 40.9 %,
respectively. Sequencing analysis of PCR products showed that typical nucleotide insertions and
deletions, caused by repairing double-strand DNA breaks during the error-prone non-
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homologous end joining process, were generated in each of the targeted CFTR loci. We also
isolated single cell-derived sheep fetal fibroblast colonies by limiting dilution following
transfection. The colony screening with the PCR/RFLP assay confirmed that we achieved
targeted gene disruption in 10/51 (19.6%) colonies for exon 2 (5 colonies with biallelic and 5
with monoallelic CFTR gene disruption), and in 17/49 (34.7%) cell colonies for exon 11(13 with
biallelic and 4 with monoallelic). In conclusion, we demonstrate that CRISPR/Cas9 is a highly
efficient system for generating targeted mutations in CFTR gene in sheep fetal fibroblasts. These
cells will be subsequently used for SCNT to generate sheep models of CF.

P4: DNA Methylation and Gene Expression Levels in Hypothalamus and Ovary of Capra hircus
Across the Genome
Stefano Frattini1, Barbara Lazzari2,3, Emanuele Capra2, Andrea Talenti1, Beatrice Coizet1,
Stephanie D. McKay4, Alessandra Stella2,3, Giulio Pagnacco1, Paola Crepaldi1
1
Department of Veterinary Medicine, University of Milan, Milan, Italy; 2 Institute of
Agricultural Biology and Biotechnology, National Research Council UOS of Lodi, Lodi, Italy;
3
PTP - Science Park, Lodi, Italy, 4 Department of Animal & Veterinary Sciences University of
Vermont, Burlington, VT, USA
Hypothalamus and ovary are two key organs of the female reproduction system of mammals.
Their role in controlling ovulation is well known, but the epigenetic mechanisms behind it, such
as DNA methylation, remain unclear. Goats are an important source of milk, meat and fiber,
especially in developing countries. Despite this, among economically relevant livestock species,
they are still poorly investigated from a genomic point of view. The aim of this work is to find a
relation between expression levels and methylation levels, in order to understand how
methylation peaks in different gene regions affect gene expression in goat hypothalamus and
ovary. Genome-wide methylated CpG detection and gene expression analysis in hypothalamus
and ovary of three adult Saanen goats were performed. Animals in the study were managed
according to the existing European Directive 2010/63/EU on the protection of animals used for
scientific purposes. For the methylome analysis DNA binding domain sequencing (MBD-seq)
with enrichment of methylated DNA fragments was performed. Gene expression was evaluated
by RNA-Seq analysis. Sequencing was accomplished with Hiseq 2000 Illumina. Around 23-37
million raw sequencing reads were generated from each sample for the methylome analysis.
Methylation distribution was investigated in six different genomic regions: promoter, intron,
exon, downstream of gene, distal and intergenic. Matching the methylation pattern in
hypothalamus and ovaries in contrast to their transcriptome allowed the identification of genomic
regions in which methylation peaks most affect gene expression. Hypothalamus showed a highly
significant negative correlation (P<0.001) between methylation peaks in promoter and in
downstream regions and gene expression. A positive correlation (P<0.001) was observed within
exons. Conversely, ovary did not show any significant consistent correlation between gene
expression and methylation. This work provides evidence for a clearer understanding of the
epigenetic mechanisms underlying gene regulation. A more accurate annotation of the goat
genome will be necessary for a deeper insight in the role of DNA methylation in gene expression
in Capra hircus, a candidate model species for other mammals.
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P5: Effect of Neuromedin U on Pig Immune Regulation
Xiang Li, Xiaoliang Li, Wenna Qiao, Zhiyu Ma, Juan Su, Zhihai Lei
College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu, P.R. China
Neuromedin U (NMU) is a conserved mammalian neuropeptide discovered in the 1980s, and
found in two forms, NMU-25 and NMU-8. Wide distribution of NMU in animal organs suggests
that NMU is involved in multiple physiological functions, including immune regulation.
However, the role of NMU in pig immune regulation has not been reported. To study the effect
of NMU on pig immune regulation, we cloned and detected the expression of NMU and its
receptors in pig lymphatic organs and immune cells. We also investigated the effect of NMU on
cytokine secretion after injection of (0, 5, 15, 45 nmol) NMU into the intracerebral ventricle
(i.c.v) of 16 pigs (n=4 for each group), and the effect of (0.1～1000 nM) NMU on cytokine
secretion in cultured dendritic cells and natural kill (NK) cells using ELISA and RIA methods.
The results were as follows: 1) NMU and its receptors were expressed in lymphatic organs,
cultured dendritic cells and NK cells. 2) NMU stimulated IL-1β, IL-6, IL-8, TNF-α and IL-10
secretion (P＜0.05) post-injection in a time- and dose-dependent manner, compared with the
control group. 3) NMU increased IL-8, IL-6 and IL-13 secretion and reduced IL-10 secretion (P
＜0.05) in cultured dendritic cells. 4) NMU enhanced the killing activity of cultured NK cells,
stimulated IFN-γ secretion and inhibited IL-10 secretion (P＜0.05) in NK cells in a time- and
dose-dependent manner. This study suggests that NMU has the role in pig immune regulation
through its effect on cytokine secretion and increasing killing activity of NK cells. Key words:
NMU, Pig, NK cell, Dendritic cell, cytokine, immune regulation

P6: Effect of Unbalanced Pedigree on Genetic Evaluation in Tunisian Holstein Cows
Yosra Ressaissi1, M. Ben Hamouda2
1
Departement des Sciences Animales, Institut National Agronomique de Tunisie, 43 Avenue
Charle Nicolle 1082-Tunis-Mahrajène-Tunisie. 2Institut National de recherches agronomiques de
Tunisie, Rue Hédi Karray-2049 Ariana Tunis.
The pedigree quality was tested on the genetic evaluation process using 3 files. The first file was
the original one which included the whole cows from which two extra pedigrees were generated:
a file with only cows whose mothers are known and a file with only cows who’s both parents are
known. A uni-trait animal model was fitted to 305-day dairy records (MY305) and counting on
the restricted maximum likelihood procedure, the construction of the entire relationship matrix
between cows and their ancestors was considered. The correlations of Pearson (r) and the
distribution of the genetic deviation by flocks were made to appreciate relationship between the
breeding values and to estimate genetic diversity according to the available genealogical
information. Heritabilities were around 0.15 and 0.39 and genetic correlations have varied from
0.82 to 0.94. Using the balanced pedigrees, the genetic parameters were ameliorated and the
coefficients of correlation were all positive while they were found to be higher between the
predicted values using the balanced pedigrees. The distribution of the genetic variability was
different according to the used pedigree. The heterogeneity in animal identification generates an
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unbalanced pedigree of poor quality which penalizes the appropriate combination of the
performances with the genealogical information. Consequently, the relevance of genetic
evaluation and the estimation of genetic variability will be affected.

P7: Establish of Immortalized Cell Line for Improving the Production Efficiency of the
Disease-model Pigs
Seon-Ung Hwang1,2, Junchul David Yoon1,2, Kiyoung Eun3, Hyunggee Kim3,* and Sang- Hwan
Hyun1,2*
1

Laboratory of Veterinary Embryology and Biotechnology, Veterinary Medical Center and
College of Veterinary Medicine, Chungbuk National University, 1 Chungdae-ro, Seowon-gu,
Cheongju 28644, Republic of Korea; 2Institute of Stem Cell & Regenerative Medicine,
Chungbuk National University, 1 Chungdae-ro, Seowon-gu, Cheongju 28644, Republic of
Korea; ³Department of Biotechnology, School of Life Sciences and Biotechnology, Korea
University, Seoul 02841, Republic of Korea.
Production efficiency of disease-model pigs using somatic cell nuclear transfer (SCNT) is very
low. It is probably because of senescence and the characteristics of the transgene. These make
limitations in a pregnancy and a production of disease-model pigs. In this study, we introduce
SV40LT oncogene into the fibroblast cells in order to establish immortalized transgenic cell line
for producing the disease-model pigs. As a result, SV40LT cell lines showed that, even though a
high passage, the normal cell morphology was observed with active cell division. We then
evaluated the effect of SV40LT oncogene on transgenic SCNT embryo development. The
cleavage rates (73.8±4.0 and 48.6±2.4 in the normal and SV40LT group, respectively; P<0.05)
and blastocyst formation rates (19.5±1.2 and 5.6±1.8 in the normal and SV40LT group,
respectively; P<0.05) of transgenic SCNT embryos was significantly lower than the case of using
normal cells. In conclusion, the SV40LT inserted cell line showed active proliferation in the
fibroblast state. However, that is not suitable for somatic cell nuclear transfer. To overcome this,
the introduction of the induction system in cell lines, such asecdysone-inducible gene switch,
tetracycline-inducible system and Gal4/UAS system, is required to increase the production
efficiency of the disease-model pigs. Keywords: Porcine, SCNT, SV40LT
This work was supported, in part, by a grant from the "Cooperative Research Program for
Agriculture Science & Technology Development (Project No. PJ011288, PJ011077)", and the
"Ministry of Trade, Industry & Energy(MOTIE), Korea Institute for Advancement of
Technology(KIAT) through the Leading Industry Development for Economic Region (Project
No. R0004357)", Republic of Korea.
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P8: Expansion and Differentiation of Isolated Porcine GFAP-CreERT2 Neural Stem Cells Using
Neurosphere Assay
Eunhye Kim1, Hyunggee Kim2 and Sang-Hwan Hyun1,*
1
Institute for Stem Cell & Regenerative Medicine (ISCRM), Chungbuk National University
& Laboratory of Veterinary Embryology and Biotechnology (VETEMBIO), College of
Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea; 2School of
Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea
In this study, we used the neural stem cells (pGFAP-CreERT2-NSCs) from the transgenic piglet
with expression of CreERT2, a fusion protein of the DNA recombinase Cre and mutated ligandbinding domain of the human estrogen receptor, under the control of the GFAP promoter. The
primary culture from tissue of porcine CreERT2 brain led to floating spherical masses of cells
and quantitative analysis indicated a yield of 2.50±0.44 primary spheres per 1,000 viable cells
from the neocortex, versus 12.92±1.67 primary spheres per 1,000 viable cells from the
periventricular region (PVR) including subventricular zone (SVZ). Secondary spheres
(6.67±1.10 spheres from neocortex versus 23.08±1.96 spheres from PVR cells) were formed
from primary spheres at 10 days after passage. Tertiary spheres (8.42±0.99 spheres from
neocortex versus 23.08±1.91 spheres from PVR cells) could also be obtained after a second
passage indicating that they were proliferating in vitro. The CreERT2-NSCs showed normal
36+XY karyotype with all analyzed metaphases free of any discernable cytogenetic
abnormalities and representative NSC markers such as NESTIN, SOX2 and VIMENTIN. After
differentiation, we were able to obtain populations of astrocytes and neurons expressing GFAP
and TUJ1, respectively. Although further studies will be needed, we developed a novel platform
for expansion and neural commitment of the isolated GFAP promoter-driven CreERT2-NSCs
which would be considered a useful tool for study of central nervous system diseases.
This work was supported, in part, by a grant from the “Cooperative Research Program for
Agriculture Science & Technology Development (Project No. PJ011288, PJ011077)", the
Ministry of Trade, Industry & Energy (MOTIE), Korea Institute for Advancement of
Technology (KIAT) through the Leading Industry Development for Economic Region
(Project No. R0004357)“ and “Korea Institute of Planning and Evaluation for Technology in
Food, Agriculture, Forestry and Fisheries (IPET) through Advanced Production Technology
Development Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA)
(Grant number: 115103-02)”, Republic of Korea.
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P9: Four Years of Editing the Livestock Genome
Chris Proudfoot1, Simon G Lillico1, Christine Burkard1, Wenfang Tan1, Maeve Ballantyne1,
Claire Neil1, Scott C. Fahrenkrug2, Fyodor D. Urnov3, Alan J. Mileham4, Alan L.
Archibald1 & C. Bruce A. Whitelaw1.
1
The Roslin Institute and R(D)SVS, University of Edinburgh, Easter Bush Campus,
Edinburgh, EH25 9RG, UK; 2 Recombinetics Inc, 2575 University Ave. West, Suite 100, Saint
Paul, MN 55108, USA; 3 Sangamo BioSciences, Point Richmond Tech Center, 501 Canal
Boulevard, Suite A100, Richmond, CA 94804, USA; 4 Genus plc, 1525 River Road, DeForest,
WI 53532, USA.
Recent advances in genome engineering have produced a range of tools that allow the precise
modification of livestock genomes. Microinjected directly into the newly fertilised zygote,
genome editor reagents are proving to be a very effective methodology for inducing changes in
the DNA sequence at their target sites, opening up a multitude of options for genome
manipulation. This ability to modify the genome, without the necessity of transgene insertion,
allows the production of animals with designer traits such as improved disease resistance,
enhanced production values or as models of human disease. We present data detailing our
experiences with TALENs, ZFNs and CRISPR/Cas9 to induce NHEJ, HDR or deletion events in
either sheep or pigs.

P10: Identification of Transgene Insertion Sites by Target Selection and Next-Generation
Sequencing
Aaron J. Thomas1,2, Rousselene Jones1, Misha Regouski2, Irina Polejaeva2, Christopher J.
Davies1,2
1
Center for Integrated BioSystems, Utah State University, Logan, UT, USA; 2 Department of
Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
Atrial fibrillation is a serious cardiac arrhythmia for which better large animal models are
needed. A transgenic goat expressing constitutively active Transforming Growth Factor-β
(TGF-β) in the heart was created by random insertion of a construct containing the mouse αMyosin Heavy Chain promoter driving expression of a constitutively active human TGF-β gene.
Subsequent breeding of this female goat and clones of the founder animal produced three male
offspring that tested positive for the transgene. To identify the transgene insertion site(s), we
constructed sequencing libraries from genomic DNA of these goats and subjected them to target
selection using RNA baits made from the transgene construct. The resulting libraries were then
sequenced on the 454 GS FLX+. The sequence reads were aligned to the goat genome and to the
transgene construct to identify those reads that had both goat genomic sequence and insert
sequence. Two insertion sites were identified: one in the RASAL2 gene on chromosome 16 and
one in the ULK4 gene on chromosome 22. Reads from the insertion site on chromosome 16 all
mapped to only one end of the insertion site whereas reads from both ends of the insertion site on
chromosome 22 were found. This is an effective method to find the genomic location of
transgenes inserted by random insertion or to find off-target insertion events when targeted
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insertion methods are used. The insertion site sequence information was used to design PCR
primers that can be used to screen offspring of the clones to determine whether they carry one or
both chromosomes with the TGF-β transgene.

P11: Impact of Histone Acetylation Status on the In Vitro Development of Porcine Transgenic
Cloned Embryos
Biping Luo1,2, Shiqiang Ju1, Rong Rui1
1
College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu 210095,
China;
2
College of Animal Science & Technology, Jinling Institute of Technology, Nanjing, Jiangsu
210038, China
Transgenic cloning is a modern biotechnology combined transgenesis with nuclear transfer.
Around 20 years have been passed after the birth of that famous cloned sheep “Dolly”. The
somatic cell nuclear transfer used for the production of Dolly enables it possible to produce
transgenic pigs. However, the efficiency to produce transgenic cloned pigs is at low level to date.
Many factors impact on the development of transgenic cloned embryos, including epigenetic
modifications. The purpose of this study was to investigate the effects of histone deacetylase
(HDAC) inhibitor trichostatin A (TSA) on transgene expression and development of porcine
transgenic cloned embryos, specifically, focusing on effects derived from TSA-treated donor
cells or TSA-treated reconstructed embryos. The results showed that TSA treatment on
reconstructed embryos modified the acetylation status, which significantly improved the
development of porcine somatic cell nuclear transfer (SCNT) embryos in vitro, but not donor
cells. Furthermore, the treatment of reconstructed embryos with TSA enhanced expression of the
pluripotency-related gene POU5F1 and stimulated expression of the anti-apoptotic gene Bcl-2.
Enhanced green fluorescent protein (EGFP) mRNA expression of every group dropped
drastically from donor cells to blastocysts. Interestingly, TSA is likely to prevent a decline in
EGFP expression in nuclear reprogramming of porcine SCNT embryos. However, DNA
hypomethylation induced by modified histone acetylation of donor cells treated with TSA was
significantly more effective to increase EGFP expression in SCNT blastocysts. In conclusion,
acetylation status of both donor cells and reconstructed embryos modified by TSA treatment
increased transgene expression and improved nuclear reprogramming and developmental
potential of porcine transgenic SCNT embryos.
Keywords: acetylation status; development; transgene expression; TSA; EGFP; SCNT; pig
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P12: Integration of Molecular Imaging and Transgenesis for Developing Large Animal Models
Liaohai Chen1, Irina Polejaeva2, and Zhongde Wang2
1
Department of Surgery, University of Illinois at Chicago, 2Animal, Dairy, and
Veterinary Sciences Department, Utah State University, Logan, UT
Humane use of large animal models plays a critical role in understanding disease etiology and
developing therapeutics. With the significant advances in gene targeting and somatic cell nuclear
transfer, it is now feasible to produce a transgenic large animal with a latent transgene(s)
embedded in its genome. However, large animals have a longer lifespan, and the impact of
activated transgene(s), as well as the appearance of disease phenotype, may take a long time to
manifest. The integration of molecular imaging with transgenesis enables the reveal of activation
efficiencies, when, where, and the expression level of the transgene product(s). Otherwise,
questions on whether the transgene is activated in the target organ and/or whether the transgene
functionally contribute to the symptom/disease phenotype will require invasive surgical
procedures or sacrifice of the animals, which will greatly hinder the development of large animal
models. In addition, the ability to evaluate pharmacologic parameters through imaging on large
animals will significantly lower the expense and the numbers of animals needed for the preclinical studies. Recently, we used somatic cell nuclear transfer (SCNT) method to develop
mutated human K-ras transgenic goats as a potential large animal tumor model. Newborn kids
have been confirmed to bear activable K-ras oncogene (K-rasG12D) and herpes simplex viral
thymidine kinase HSV-tk gene, a well-established reporter gene. The presence of the report gene
will enable imaging the effectiveness of K-ras activation, K-ras location/expression level upon
activation in transgenic goats by Positron Emission Tomography (PET). In vitro experiments
have confirmed the transformation from normal cells to tumor cells once the transgenes were
activated. A clinical PET-CT system is being installed at USU.

P13: In Vivo Ovarian Germ Cell Transgenesis
Rhett L. Peterson, Kate C. Parkinson and Jeffrey B. Mason
Department of Animal, Dairy and Veterinary Sciences, Center for Integrated BioSystems,
School of Veterinary Medicine, Utah State University, Logan, UT, USA.
In somatic gene transfer, the recipient's pattern of gene expression is changed, but the change is
not passed on to the next generation. In germline gene transfer, the germline cells are changed
with the goal of passing on the changes to offspring. We are currently investigating in vivo gene
transfer to ovarian tissues (somatic and germline) using recombinant adeno-associated viral
vectors. Our objectives are to 1) alter ovarian gene expression in vivo to modify the influence of
the ovaries on the physiology of the recipient and 2) to use this technology to produce germlinetransmissible changes in livestock species. What makes this work unique is that we are altering
genetic influence focally (ovaries) in an otherwise normal, adult animal and these changes will
be germline-transmissible. Adult, six-month-old female CBA/J mice had their ovaries surgically
exposed to a eGFP-containing recombinant adeno-associated virus. Four weeks postoperatively,
the females were induced to ovulate and the entire reproductive tract was collected. Ovaries were
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routinely processed for histology using an anti-eGFP antibody. Ovulated oocytes were evaluated
for eGFP expression at the time of collection. Ovulated oocytes and histological ovary sections
both displayed evidence of eGFP transgene expression. Adeno-associated viral vectors normally
remain episomal in transduced cells. However, transduced oocytes, upon fertilization will
undergo meiosis exposing the 'normally episomal' transgene to meiotic recombination, similar to
the process that allows incorporation of genes using oocyte/zygote microinjection. Future work
will include in vitro fertilization of transduced oocytes, breeding of recombinant adenoassociated viral vector-exposed female mice and intra-ovarian transduction of ovaries in sheep.

P14: Large Exotic Animal Models for Heritable Neurological Disease and Cancer
Brian W. Davis, Ph.D.
Cancer Genetics and Comparative Genomics Branch, National Human Genome
Research Institute, National Institutes of Health; Bethesda, Maryland, USA.
The expanding field of high throughput genomics has allowed the exploration of other model
system for the identification of loci implicated in disease. Natural models for the study of
genetic conditions are underway in felines and canines, as well as agricultural species. The
population structure and veterinary surveillance of these organisms under human care lend
themselves very well to understanding the mechanisms that underlie common conditions shared
with humans. Recently, using RNAseq, our work has shown that canine transitional cell
carcinoma, which has orders of magnitude higher occurrence of in certain canine breeds, shares a
common somatic mutation (BRAF V600E) with several human cancers. An extension of this
work is being explored for two conditions in exotic cats, which share similar population
bottlenecks and veterinary surveillance as companion animals. In addition, their extended age in
captivity (oten twice that of the wild) aids in understanding disease associated with geriatry. Our
data shows malignant melanoma is prevalent in the captive tiger population, but is enriched in
certain breeding lines. The same is true for spinocerebellar ataxia in African lions, which is
linked to hypovitaminosis A, regardless of diet. Using whole genome and transcriptome
sequencing in collaboration with the Exotic Genome Repository (exoticgenome.org), we propose
a model that incorporates populations maintained in zoological parks with generational health
and breeding records as a proxy for human health. This not only provides mechanisms for
testing human therapies in these species, as exemplified by canines, but allows the application of
previously identified, targeted human therapies for use in these animals.
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P15: Management of Many Recessive Disorders in a Dairy Cattle Population Using Gene
Editing and Sequential Mate Allocation
John B. Cole
Animal Genomics and Improvement Laboratory, Agricultural Research Service, United States
Department of Agriculture, Beltsville, MD, USA
High-density single nucleotide polymorphism genotypes have recently been used to identify a
number of novel recessive mutations that adversely affect fertility in dairy cattle, as well as to
track conditions such as red coat color and polled. Recent findings suggest that the use of
sequential mate allocation strategies that account for increases in genomic inbreeding and the
economic impact of affected matings result in faster allele frequency changes than strategies
which do not consider inbreeding and monetary losses. However, the effect of gene editing on
selection programs also should be considered because gene editing has the potential to
dramatically change rates of allele frequency change. A simulation program developed to
evaluate dairy cattle breeding schemes was extended to include the use of CRISPR-Cas9,
TALEN, and ZFN for gene editing. A hypothetical technology with a perfect success rate was
used to establish an upper limit on attainable progress, and a case with no editing served as a
baseline for comparison. The technologies differed in the rate of success of gene editing, as well
as the success rate of the embryo transfer step, based on estimates in the literature. For purposes
of this study the number of alleles edited had no effect on success rate. The two scenarios
evaluated considered only the horned locus, or 12 recessive alleles currently segregating in the
US Holstein population. The top 1, 5, or 10 % of bulls were edited each generation, and either no
cows or the top 1 % of cows were edited. Cumulative genetic gain did not differ across scenarios
because the elite animals in the population were the ones selected for genetic modification. Gene
editing was very effective at reducing the frequency of the horned haplotype (increasing the
frequency of polled animals in the population), and allele frequencies of the 12 recessives
segregating in the US Holstein population decreased faster with editing than without. These
results suggest that gene editing is an effective tool for reducing the rate of harmful alleles in a
dairy cow population even if only a small proportion of elite animals are modified.

P16: MedSwine: Engineering Swine Genome for Biomedical Models
Bin Zang1, John Garbe2, Dan Carlson4, Scott Fahrenkrug3,4
1
Scientific computation, University of Minnesota, 200 Union St, Minneapolis, MN 55455, USA.
Minnesota Supercomputing Institute, University of Minnesota, 117 Pleasant St SE, Minneapolis,
MN 55455, USA; 2Department of Animal Science, University of Minnesota, 1364 Eckles Ave,
Saint Paul, MN 55108, USA; 3,4Recombinetics, Inc., 1246 University Avenue W, #301, Saint
Paul, MN 55104, USA
Large Animals Better Resembles Human Disorders
We firstly compared several model animals including mice, rats, zebrafish as well as pigs to find
out the resemblance of human disorders with known disease-gene relationship. By measuring the
proteome level similarity of gene sets that are related to different disorder types, we identified
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disorders in human that can be better modelled with large animals, especially pigs, than murine
models. We find that these disorders include human metabolic syndromes such as MODY, and
certain cancer types, such as breast cancer and liver carcinoma.
Imputing Human Disease-causative Mutations in Pig Genome
We collected variations presented in human genome with clinical significance from OMIM
curated disease associated genes, of which, 5,916 have been successfully annotated in current pig
genome assembly. We used protein alignment of the corresponding orthologous gene pairs to
annotate potential editing sites within the pig genome. Overall, we imputed 947 nonsynonymous
stop gained deletions, leading to partial/complete loss of function mutations, as well as 4,330
missense mutations in human genome to have corresponding pig edit sites. This result enables us
to edit the pig genome for the model of 2,484 human disorders with at least one confirmed
associated SNP.
In silico Off-target Prediction of Editing Tools
Rise of genome editing tools such as CRISPRs and TALENs gave us power to easy editing the
genome. With pre-computed nucleases, we identified 5,363 CRISPRs sit nearby a disease
associated SNP site. Among all these CRISPRs 1,603 of them sits within 20bp range of the SNP,
indicating a set of good target candidates for human disease model.
MedSwine as an Integrative Resource for Pig Models
We also present MedSwine, a one-stop resource for engineering the pig genome for human
biomedical models. MedSwine provide a resource to share aforementioned human disease
models within the context of the pig genome. It also allows users to navigate, inspect and select
putative nucleases around target mutation sites. MedSwine is under active development with
scheduled feature integration.

P17: Molecular Basis of Atrial Fibrillation in TGF-β Transgenic Goats
Misha Regouski1, Dustin H. Liechty1, 2, Arnaud Van Wettere1, 2, Heloisa M. Rutigliano1, 2, Irina
A. Polejaeva1
1
Department of Animal, Dairy, and Veterinary Sciences, Logan, UT 2School of Veterinary
Medicine, Utah State University, Logan, UT
Atrial fibrillation (AF) is one of the most prevalent cardiac arrhythmias. Studies have shown
associations between cardiac fibrosis and incidence of AF, however the underlying mechanisms
of this relationship is poorly elucidated. Our group has developed the first transgenic goat model
of cardiac fibrosis. These transgenic goats (with overexpression of human TGF-β1) provide a
unique platform to study the mechanisms underlying AF. We hypothesize that genes associated
with the TGF-β signaling pathway, fibronectin, and collagens will be upregulated in the heart
tissue of transgenic goats, as well as inflammatory cytokines. Atrial and ventricular samples
were collected from TGF-β1 transgenic goats (n=6) and wild-type controls (n=5). Transgenic
animals included in this study expressed the transgene in a cardiac specific manner and exhibited
increased atrial fibrosis and AF inducibility. Preliminary gene expression analysis was performed
following standard Fluidigm protocol (Spurgeon et al., 2008). Genes analyzed included
housekeeping controls, and those associated with TGF-β and fibrosis pathways, inflammatory
mediators, and apoptosis. Immunohistochemistry was conducted in order to characterize
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different leukocyte cell populations (CD2+, CD4+, CD8+, CD14+, CD21+, MHC-II+ and
FoxP3+ cells). Imaging was done using a high-resolution AxioCam HRC digital camera and
analyzed using AsioVision software. We expect to identify an increase in lymphocytes such as
CD2+, CD4+ and CD8+ T cells and macrophages (CD14+ and MHC-II+) in the myocardium of
transgenic goats when compared to their wild-type controls. In addition, histological sections
stained with Masson’s trichrome stain and hematoxylin and eosin were analyzed. Within each
section 10 randomly selected fields of view were photographed using an Olympus DP 26 digital
microscope camera and CellSens digital imaging software (Olympus Corporation). Fibrosis
quantification was determined by measuring percentage area occupied by blue staining
(Masson’s trichrome stain) of total surface area using Photoshop CS6 (Adobe Systems).
Cardiomyocyte diameter was assessed by measuring distance of the narrowest plane across the
cell nucleus for 100 cells from each atrium and ventricle from control and transgenic goats. Data
generated by these experiments will aid in the identification of the molecular basis of cardiac
fibrosis and atrial fibrillation in order to facilitate better treatment options for patients with AF.

P18: Novel Accessible Method to Produce Porcine Chimeric Embryo
Junchul David Yoon1, Eunsong Lee2 and Sang-Hwan Hyun1*
1

Institute for Stem Cell & Regenerative Medicine (ISCRM), Chungbuk National University,
Cheongju, 28644, Republic of Korea, 2Laboratory of Theriogenology, College of Veterinary
Medicine, Kangwon National University, Kangwon, Republic of Korea
Since the pluripotent stem cells (PSC) was discovered including embryonic stem cells (ESC) and
induced pluripotent stem cells (iPSC), the PSCs was look forward with the keenest anticipation
to differentiate functioning organs in regenerative medicine. Recent decade, the studies for
generation of functional organs have been advanced remarkably with underlying mechanisms for
production of chimeric animals. However, the procedure of chimeric animal production is
intricate and it became a major reason of low in vitro production efficiency. The purpose of this
study is to investigate to establish the novel accessible method to produce porcine chimeric
embryo. In first, we produced EGFP-marked porcine fibroblast, and then established the EGFP
labeled porcine ES-like cells via somatic cells nuclear transfer (EGFP-ntESC). The produced
ntESC were injected into 2-, 4-, and 8 cells stage of cleaved parthenogenesis embryo at day 2
under microscope with manipulators. We investigated chimeric embryo development, and
counted total cell number and EGFP-labeled cell number from achieved blastocysts. Data were
analyzed by ANOVA followed by Duncan using SPSS (Statistical Package for Social Science).
After day 5 of in vitro chimeric embryo culture (IVC), ES cells injected on the 4- and 8 cells
stage groups showed significantly higher total blastocyst (49.6% VS 63.9% and 65.6%,
respectively) and expended blastocyst formation rate (30.2% VS 50.7% and 52.2%, respectively)
compared with ES cell injected on the 2 cell stage group. Under epifluorescence (460 nm)
analysis, the 8 cell groups showed significantly higher EGFP-ntESCs number and distribution in
achieved blastocyst compared with 2 cell group (4.0 and 6.0% VS 1.8 and 3.1%), even though
we could not find any significant differences on blastocyst total cell numbers (60.6, 73.8, and
87.6, respectively). In conclusion, ES cell injection on 8 cell stage is applicable to produce

40

porcine chimeric embryo. However, improvement of injected ES distribution in blastocyst
required for effective production of in vitro chimeric embryo.
Keywords: porcine, Chimeric embryo, EGFP
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P19: Reduced Gene Expression and Mitochondrial Function in Porcine Donor-fibroblasts
Treated with CPI-613 or PS48 Does Not Negatively Impact Subsequent In Vitro Development
After Somatic Cell Nuclear Transfer
Bethany R. Mordhorst , Stephanie L. Murphy, Joshua A. Benne, Bethany K. Redel, Lee D.
Spate, Kevin D. Wells, Jonathan A. Green, Randall S. Prather.
Department of Animal Science, University of Missouri, Columbia, MO, United States.
Early embryos exhibit characteristics of a Warburg Effect (WE)-like metabolism. A hallmark of
the WE is predominate use of glycolysis for energy production as opposed to the tricarboxylic
acid (TCA) cycle. In cancer cells increased signaling of the PI3K pathway is correlated with an
increase in glucose metabolism consistent with the WE. PS48 stimulates the PI3K pathway and
CPI-613 inhibits pyruvate dehydrogenase. Both compounds should decrease mitochondrial use
of the TCA cycle and promote the PI3K pathway. The goal was to achieve a WE-like effect in
donor-cells prior to nuclear transfer (NT) by treating day 35 porcine fetal fibroblasts for 7 days.
Data were analyzed for main effect of drug via GLM procedure of SAS 9.4 (Cary, NC). JC-10
was used to determine the mitochondrial membrane potential (Δψm). The percentage of cells
with high Δψm decreased (P <0.01) with 10µM PS48 (33.4%), CPI 100µM (1.76%), or the
combination (MIX; 2.81%) compared to control (CON; 46.5 ±3.3%). Expression of mRNA was
measured by qPCR ΔΔct method. CPI and PS48 decreased PKM M1 variant expression
compared with control (P< 0.01). Treatments decrease Δψm and PKM M1 abundance, therefore
metabolism of these potential donor cells may be more WE-like. Fibroblasts treated with CPI,
PS48, and MIX were used for NT in enucleated oocytes. Cleavage and blastocyst percentages,
blastocyst cell number, and TUNEL positive cell number were not augmented by donor-cell
treatment (P >0.14). Drug treatments were tested in the culture of SCNT embryos derived from
non-drug-treated fibroblasts. Blastocyst development was impacted by drug culture treatment
(P= 0.05): PS48 and CON had higher percentages (43.3 and 41.2%) compared to CPI and MIX
(33.6 and 32.7 ±2.9%). TUNEL positive cell number was increased in MIX embryos vs. other
treatments (P =0.01; MIX =2.1 vs. ≤1.4 ±0.26 in other treatments). Zygotic cleavage rate and cell
number within blastocysts were not altered with embryonic drug culture (P ≥ 0.07). To date, we
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have 3 successful day-35 fetal collections resultant from embryo transfers of PS48 and CPI
donor-treated clones. Future experiments will further investigate embryonic metabolic
programming. Funded by Food for the 21st Century and NIH R01HD080636.

P20: Reprogramming Bovine Fibroblasts to Pluripotency by Fusion to Mouse Embryonic Stem
Cells
Maria-Cristina Villafranca, Kaylyn R. Williams, Will H. Eyestone
Department of Large Animal Clinical Sciences, Virginia-Maryland Regional College of
Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA
Embryonic stem cells (ESCs) are pluripotent cell lines derived from preimplantation embryos of
mice, humans and non-human primates. Induced pluripotent cells (iPSCs) are generated from
differentiated cells by ectopic expression of transcription factors found in ESCs, and are
morphologically and functionally equivalent to ESCs. The bovine is an important agricultural
species for which neither ESCs nor iPSCs exist. Traditional transcription-factor based
reprogramming, even in the presence of reprogramming enhancers, is insufficient to reprogram
bovine somatic cells to pluripotency. Mouse and human somatic nuclei can be reprogrammed to
pluripotency when fused to mouse ESCs (mESCs), suggesting that mESC cytoplasm contains
reprogramming factors. We hypothesize that mESCs will reprogram bovine somatic cells upon
fusion and plan to use this model to identify additional/alternative reprogramming factors. We
developed a cell fusion method using polyethylene glycol and dimethyl sulfoxide (DMSO).
Additionally, we designed a method to detect and select heterotypic (i.e. mESC/somatic cell;
heterokaryons) from homotypic fusions (i.e. same cell type fusion products; homokaryons).
Bovine fibroblasts (BFs) were transduced with a polycistronic lentiviral vector harboring a CMV
promoter-driven cyan fluorescent protein (CFP) and an Oct4 promoter-driven GFP reporter, as
well as a puromycin selectable marker. We transduced mESCs with a lentiviral vector harboring
a CMV promoter-driven monomeric red fluorescent protein (mRFP) reporter. With these tools in
place, selected BFs and mESCs were fused and monitored for reprogramming by upregulation of
Oct4-driven GFP expression. We observed expression of Oct4-driven GFP in cells expressing
both CMV and mRFP. We plan to screen heterokaryons for differentially expressed genes using
RNA-seq. To avoid lentiviral integrations, we designed an alternative method to label BFs and
mESCs using fluorescently labeled antibodies. Upon fusion, heterokaryons were labeled with
anti-bovine CD44 and anti-mouse SSEA-1 antibodies. Heterokaryons positive for both markers
were manually selected using a micromanipulator. We are currently performing the necessary
steps for RNA-seq using RNA from <20 heterokaryons. Future research will involve testing
candidate reprogramming genes for reprogramming activity by forced expression in BFs. We
plan to further characterize the cells obtained with our new set of candidate factors by
establishing comparisons with cells reprogrammed with currently known reprogramming factors.
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P21: Targeted Gene Knock-in by CRISPR/Cas Ribonucleoproteins in Porcine Zygotes
Ki-Eun Park1,2,3, Anne Powell2, Shelley E.S. Sandmaier1,2, Chan-Mi Kim1,2, Alan Mileham4,
David M. Donovan2, and Bhanu P. Telugu1,2,3
1
University of Maryland, Animal and Avian Sciences, College Park, MD, USA; 2 USDA-ARS,
Animal Bioscience and Biotechnology Laboratory, Beltsville, MD, USA; 3 Livestock Genomix,
Reisterstown, USA; 4 Genus plc, DeForest, WI, USA
The domestic pig is an important “dual purpose” animal model for agricultural and biomedical
applications. There is an emerging consensus in the biomedical community that there is a
requirement for large animal models such as pigs that can either serve as an alternative, or
complement investigations from the mouse. However, the use of pig has not proven popular to
date due in part to technical difficulties and time required in generating desired genetic
modifications. In this regard, the ability to directly modify the genome in the zygote and generate
edited animals is highly desirable. This report demonstrates for the first time, the generation of
gene knock-in animals by direct injection of Cas9 ribonucleoprotein complex and short stretches
of DNA sequences into porcine zygotes. The Cas9 protein from Streptococcus pyogenes was
precomplexed with a single guide RNA targeting downstream of the ubiquitously expressed
COL1A gene, and co-injected with a single-stranded repair template into porcine zygotes. Using
this approach, pigs that carry pseudo attP sites within the COL1A locus to enable phiC31
integrase mediated introduction of transgenes have been generated. This new route for genome
engineering in pigs via zygote injection should greatly enhance applications in both agriculture
and biomedicine.

P22: TCET: A Novel Non-surgical Embryo Transfer Device
Ruonan Liu1, Yanping Miao1, Xinchong Duan1, Mo Guan2, Xiangyun Li1
1
College of Animal Science and Technology, Agricultural University of Hebei, Baoding,
Hebei 071000, China. 2 Medical Research Council, Mary Lyon Centre, Harwell Campus,
Oxfordshire, OX11 0RD, UK
Although non-surgical transfer of embryos in mice has many advantages over a surgical method,
the variable success of non-surgical transfer has hampered its acceptance and use. In our studies,
we discovered that the uterine injury and embryo loss during the procedure are the main causes
of the variable success for non-surgical transfer. We found that the material and shape of the
transfer catheter, the implantation-related factors, the volume of transfer medium and the
techniques of transfer significantly affected embryo implantation. Therefore, we developed a
novel non-surgical device - TCET (Transcervical Embryo Transfer, Elim Springs Biotech Ltd,
UK). The device comprises of an arched, thin, soft tip catheter with blunt ends, which will avoid
or minimize the risk of scratching the endometrium or puncturing the uterine horn during the
procedure, and the right length of the catheter tip can improve the delivery of the embryos in the
best position in the uterus for successful implantation. We also refined the transfer techniques
and the component and volume of transfer medium, which significantly reduces the uterine
injury and embryo loss and improves the embryo implantation. In these experiments reported
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here, 62 blastocysts from natural cycle CD1 mice were non-surgically transferred into the uteri
of 8 CD1 recipient females (2.5d). As the control, 116 embryos were surgically transferred into
the uteri of 15 CD1 recipient females (2.5d). The results showed that 100% recipient females
(8/8) got pregnant and gave birth to 51 live pups (82.2%) from TCET transfer. The results from
the control group were: 93.3% pregnancy rate (15/14) and 70.6% birth rate (82/116). Compared
with surgical embryo transfer, the procedure of TCET transfer is much simpler, quicker, easier,
markedly less traumatic and less stressful to the recipient females. In Summary, we established a
novel and efficient non-surgical embryo transfer using TCET here, which could be an alternative
to surgical embryo transfer. In addition, this non-surgical embryo transfer technique in mice
establishes an animal model for the study of rats, cattle, other large animals and human embryo
transfer techniques.

P23: The International Society for Transgenic Technologies – Large Animal/Non-Rodent
Initiative
Jan Parker-Thornburg1, Bruce Whitelaw2, Martina Crispo3
1
ISTT, Inc. President, Department of Genetics, MD Anderson Cancer Center, Houston
TX USA; 2 The Roslin Institute, University of Edinburgh, Midlothian UK; 3 ISTT, Inc. Board
Member, Transgenic and Experiment Animal Unit, Institut Pasteur, Montevideo, UR
The International Society for Transgenic Technologies, Inc. (ISTT, Inc.) was founded in January
2006 in Spain, and was reincorporated in the USA in May, 2013. The Society seeks to foster
communication and sharing of technology, to enhance scientific research, to advance the field of
animal transgenesis, particularly as it applies to useful experimental models in biology, medicine
and biotechnology, and to represent the interest of scientists, technicians, and graduate students
working in the field of transgenic technologies. The ISTT sponsors a series of periodic
international meetings known as the Transgenic Technology (TT) Meetings. At TT2016, held in
Prague CZ (March 2016), the ISTT instituted a Large Animal/non-Rodent initiative, to be
headed by Bruce Whitelaw (Roslin Institute) and Martina Crispo (Institute Pasteur, Uruguay,
ISTT Board member). The ISTT Board encourages all investigators working in non-rodent
models to join and contribute to this effort.
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P24: To Make an Alzheimer’s Disease (AD) Sheep Model Using CRISPR Genome Editing
Jun Liu1, Jen M. Kelly2, Clive J. McLaughlan3, C. Simon Bawden3, Susanne J. Reid4, Russell G.
Snell4, Paul J. Verma1,2
1
Stem Cell and Genetic Engineering Group, Department of Materials Engineering, Monash
University, Clayton, VIC, Australia; 2 Reproductive Biology, Turretfield Research Centre, South
Australian Research and Development Institute, Rosedale, SA, Australia; 3 Molecular Biology
Laboratory, South Australian Research and Development Institute, Roseworthy, SA, Australia; 4
Centre for Brain Research, School of Biological Sciences, University of Auckland, Auckland,
New Zealand
Objective: Presenilin 1, encoded by the PSEN1 gene, is one of four core proteins in the gammasecretase complex, which mediates regulated proteolysis of several proteins in the cell, including
the amyloid precursor protein (APP). Gamma-secretase activity generates specific beta-amyloid
42) accumulates to form the intraneuronal plaques associated with AD. A simple glutamic acidto-alanine mutation at codon 280 (E280A) in PSEN1 alters the activity of gamma-secretase and
results in increased levels of the toxic 42 peptide. To attempt creation of AD sheep, the project
aims to replace the equivalent glutamic acid codon in the sheep PSEN1 protein (E277) with an
alanine codon.
Methods: A pair of 20bp gRNA was designed using online CRISPR design tools. The gRNAs
were annealed and sub-cloned into pSpCas9(BB) and lentiCRISPRv2 backbone vectors using
Zhang’s lab protocols. Two HDR oligos of 202bp and 194pb, respectively, were designed and
synthesized by IDT.
Results:
Functionality of the CRISPR in HEK293T cells: Reporter vectors were constructed using
GeneArt genomic cleavage selection kit. Using lipofactamine 3000 transfection reagents, the
reporter and pSpCas9(BB)-sgRNA vectors were transfected into HEK293T cells. 20 h post
transfection, positive OFP cells were detected under a fluorescence microscope. FACS analysis
showed that 25.6% of the cells were OFP positive.
Functionality of the CRISPR in sheep iPS cells: lentiCRISPRv2-sgRNA#2 was co-transfected
with packaging plasmids pMD2.D and psPAX2 into HEK293T cells to produce lentiviral
particles, which were then transduced into sheep iPS cells using Fugene 6 reagent according to
manufacturer’s instructions. 48 h later, the cells were cultured in medium supplemented with 100
ng/ml puromycin. Genomic DNA was extracted from the surviving colonies. T7EI assay showed
two additional digested products as well as full-length PCR products. Subsequent sequencing
analyses showed that random-sized Indel mutations were created at the desired locus in the iPS
cell colonies.
Generation of targeted sheep mutants by embryo injection of CRISPR mRNA: A mixture of
Cas9 mRNA, sgRNA, and HDR single-strand oligo were injected into the sheep one-cell stage
embryos. The injected embryos were cultured in vitro for blastocyst formation. Genomic DNA
was extracted from the blastocysts and subjected to genotyping. Out of 100 sequenced
blastocysts, 2 embryos showed the HDR mutation in the genome.
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Our transgenic goats are the first of their kind, and may help doctors
understand and treat the most common heart arrhythmia in humans.
Learn more about them in Session 3 of the Large Animal Genetic
Engineering Summit and in the August 2016 issue of the Journal of
Cardiovascular Electrophysiology.
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